About: admin

Website
https://cambodiapr.com

Posts by admin:

Government Provides Transition Grants to Support Gambling Charities

admin

(AsiaGameHub) -   The British government is working to alleviate the financial strain on charities addressing gambling harm as they navigate a new, and at times contentious, funding system. According to the Department for Culture, Media and Sport (DCMS), which oversees gambling regulation in the UK, the statutory research, education, and treatment (RET) levy has generated nearly £120 million in its inaugural year. This substantial amount is earmarked specifically for research into, prevention of, and treatment for gambling-related harm. However, the transition from the previous funding arrangements to the new model has posed difficulties for some charitable organizations. To address these challenges, the DCMS has established a three-month transition grant fund. This grant will be accessible to UK charities focused on gambling harm from April 1 to June 1, 2026. In instances where the DCMS makes a decision after April 1, charities will be permitted to submit claims retroactively. Charities will be required to meet specific eligibility criteria to be considered for a grant. Eligible organizations must have been engaged in 'relevant activity' in March 2026 to support service users in England. Furthermore, they must have previously applied for and been unsuccessful in securing funding from the gambling levy through either the Gambling Harms Prevention VCSE Grant Fund or the Gambling Harms Treatment VCSE Grant Fund. The purpose of this grant is to cover staffing costs and associated overheads necessary for the continued operation of charity services. Capital expenditures, defined as any spending that results in the creation or improvement of an asset valued at over £2,000, are not eligible for funding. Organizations have until April 30, 2026, to submit their grant applications. Charities navigate a controversial shift The levy was a key component of the Gambling Act review, replacing the former system where operators voluntarily contributed 1% of their revenue to GambleAware. GambleAware then managed the commissioning of RET projects nationwide. Invoices for the statutory levy were first issued by the UK Gambling Commission (UKGC) on September 1, 2025, with a payment deadline of October 1, 2025. The levy is now an annual obligation for licensed operators, with invoices dispatched on September 1 each year. However, the introduction of the levy has not been without controversy, and several charities have expressed concerns regarding the long-term viability of the UK's gambling harm research, education, and treatment system under the new funding structure. NHS England, which is undergoing restructuring, has assumed responsibility for treatment funding. The Office for Health Improvement and Disparities (OHID) will oversee prevention efforts, and UK Research and Innovation (UKRI) will manage research initiatives. GambleAware ceased operations earlier this month, as its commissioning functions have been effectively transferred to the NHS. The charity had long advocated for the establishment of a statutory levy, but with itself retaining the lead role in commissioning. Various charitable organizations voiced alarm at these changes when the Gambling Act review White Paper was published in April 2023, and have continued to do so. For instance, the Gambling Lived Experience Network (GLEN) shared some frustrations on LinkedIn just last week. However, the organization did offer some commendation for OHID, describing its performance as significantly better than that of NHS England and UKRI. Is there any going back? Regardless of the opinions held by charities, it appears that the statutory levy is a permanent fixture. Even if the government were to reconsider its position, such a significant undertaking would require considerable time to reverse. The process of commissioning services is also well underway. In Scotland, the devolved government has begun allocating its £7.9 million share of the UK-wide gambling levy. These funds will be distributed among the NHS, local authority partners, and the third sector, which includes charities. Scotland's Public Health Minister, Jenni Minto, stated: “Gambling harm is a significant issue affecting far too many people in Scotland. It impacts not only individuals who gamble but also their families, relationships, communities, and society as a whole. “We are already working diligently with partners to mitigate this, and these awards represent a major step forward. This funding will support a variety of projects and programs for individuals dealing with what is often an unseen issue. “Data indicates that over two percent of Scottish adults – more than 90,000 individuals – may be problem gamblers. The funding provides a balanced approach across the third sector, including community and voluntary organizations, and services delivered through the NHS and local authorities.” The largest beneficiaries include the RCA Trust (£1 million), Public Health Scotland (£967,000), NHS Greater Glasgow and Clyde (£926,000), Fast Forward (£561,000), Citizens Advice Scotland (£450,000), and Simon Community Scotland (£445,000). Other recipients are Gambling With Lives (£124,000), Charity Space Scotland (£47,000), Scottish Ambulance Service (£45,000), Young Scot (£30,000), and Dundee and Angus College (£52,000). The RCA Trust, the largest recipient, offers counseling services for individuals affected by gambling-related harm and other conditions such as drug and alcohol abuse. Andy Todd, a spokesperson for the charity, commented: “The funding provided by the Scottish Government will be crucial for the ongoing delivery of prevention, education, training, treatment, and support for those impacted by gambling harms across Scotland. “With gambling harms now being addressed through a public health model, we look forward to collaborating with partners to reduce harms by expanding service provision, decreasing stigma, and working with lived experience perspectives to integrate policy and practice among frontline staff.” The distribution of gambling harm treatment funding in Scotland follows the Welsh government's announcement of how its share of the RET levy funds would be allocated nine months prior. However, there is still no confirmation regarding how funds will be utilized in England. Overall, the government anticipates raising between £90 million and £100 million annually from the levy. According to the DCMS, this target was exceeded in its first year, yet there remains no clarity on how these funds will be spent in England, the UK's largest nation. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

ស្មែក Ḩnarej Ꮤরម Ḥırkean တἈច အဝောင်းလော အဖြစ် တကယ်တြင်သည်။

admin

(SeaPRwire) -   អ៊ីរ៉ង់ហាក់ដូចជាកំពុងបង្កើតខ្លួនជាអ្នកឆ្លងកាត់សមុទ្រហរមូស ដែលជាសរសៃឈាមដ៏សំខាន់បំផុតរបស់ពិភពលោកសម្រាប់ការដឹកជញ្ជូនប្រេង។ សកម្មភាពនេះអាចពង្រឹងការក្តាប់ជាប្រជាជនពិតរបស់ទេហេរ៉ងលើផ្លូវទឹកដ៏សំខាន់នេះ និងធ្វើឱ្យសមត្ថភាពរបស់ខ្លួនក្នុងការបញ្ជូនប្រេងផ្ទាល់ខ្លួនទៅកាន់ប្រទេសចិនកាន់តែមានលក្ខណៈផ្លូវការ។ សារទំនាក់ទំនងរបស់អ៊ីរ៉ង់ទៅកាន់អាជ្ញាធរដឹកជញ្ជូនសមុទ្រអង្គការសហប្រជាជាតិ និងបទពិសោធន៍នៃកប៉ាល់ដែលឆ្លងកាត់ច្រកសមុទ្រនេះបង្ហាញពីការបង្កើតអ្វីមួយស្រដៀងនឹង "ប៉ុស្តិ៍ប្រាក់ឆ្លងកាត់"។ កប៉ាល់ត្រូវតែចូលទៅក្នុងទឹកដីសមុទ្រអ៊ីរ៉ង់ និងត្រូវពិនិត្យដោយក្រុមយោធាកងឆ្មាំបដិវត្តន៍អ៊ីស្លាមអ៊ីរ៉ង់។ យ៉ាងហោចណាស់កប៉ាល់ចំនួន ២ គ្រឿងបានបង់ប្រាក់សម្រាប់ការឆ្លងកាត់។ ចរាចរណ៍ឆ្លងកាត់ច្រកសមុទ្រនេះបានធ្លាក់ចុះ ៩០% ចាប់តាំងពីការចាប់ផ្តើមសង្គ្រាមអ៊ីរ៉ង់ ដែលធ្វើឱ្យតម្លៃប្រេងពិភពលោកកើនឡើងយ៉ាងខ្លាំង និងបង្កឱ្យមានកង្វះដ៏គួរឱ្យព្រួយបារម្ភដល់ប្រទេសអាស៊ីដែលទទួលបានប្រេងពីបណ្តាប្រទេសឈូងសមុទ្រពែរ្សតាមរយៈច្រកសមុទ្រនេះ។ មានតែកប៉ាល់ប្រមាណ ១៥០ គ្រឿងប៉ុណ្ណោះ រួមទាំងកប៉ាល់ដឹកប្រេង និងកប៉ាល់ដឹកធុងសមុទ្រ ដែលបានឆ្លងកាត់ចាប់តាំងពីថ្ងៃទី ១ ខែមីនា យោងតាមក្រុមហ៊ុនផ្តល់ព័ត៌មានដឹកជញ្ជូនសមុទ្រ Lloyd’s List Intelligence។ នោះគឺច្រើនជាងចរាចរណ៍ធម្មតាក្នុងមួយថ្ងៃមុនសង្គ្រាមបន្តិចប៉ុណ្ណោះ។ កំពង់ផែកោះខាគរបស់អ៊ីរ៉ង់បានផ្ទុកប្រេងចំនួន ១,៦ លានបារ៉ែលក្នុងខែមីនា ដែលស្ទើរតែមិនផ្លាស់ប្តូរអ្វីសោះពីចំនួនផ្ទុកប្រចាំខែមុនសង្គ្រាម យោងតាមក្រុមហ៊ុនវិភាគទិន្នន័យ Kpler។ អតិថិជនភាគច្រើនគឺរោងចម្រាញ់ប្រេងឯកជនតូចៗនៅប្រទេសចិន ដែលមិនយកចិត្តទុកដាក់ចំពោះទណ្ឌកម្មរបស់សហរដ្ឋអាមេរិក។ កប៉ាល់ភាគច្រើនដែលឆ្លងកាត់បានក្នុងប៉ុន្មានសប្តាហ៍ថ្មីៗនេះធ្វើដំណើរទៅទិសខាងកើត ចេញពីឈូងសមុទ្រ។ កប៉ាល់ដែលទាក់ទងនឹងអ៊ីរ៉ង់មានចំនួន ២៤% នៃការឆ្លងកាត់ ប្រទេសក្រិក ១៨% និងចិន ១០% ដែលរាប់បញ្ចូលតាមម្ចាស់កប៉ាល់ ឬការចុះបញ្ជីទង់ជាតិកប៉ាល់។ ទោះជាយ៉ាងណាក៏ដោយ នៅពេលពិនិត្យឱ្យកាន់តែច្បាស់ កប៉ាល់ដែលទាក់ទងនឹងអ៊ីរ៉ង់មានចំនួន ៦០% នៃការឆ្លងកាត់ក្នុងដំណាក់កាលដំបូងនៃសង្គ្រាម ហើយក្នុងប៉ុន្មានថ្ងៃចុងក្រោយនេះមានរហូតដល់ ៩០%។ កប៉ាល់ប្រហែលពាក់កណ្តាលបានបិទប្រព័ន្ធកំណត់អត្តសញ្ញាណវិទ្យុដែលបង្ហាញទីតាំងរបស់ពួកគេមុនពេលឆ្លងកាត់ ហើយបង្ហាញខ្លួនម្តងទៀតនៅផ្នែកម្ខាងទៀតនៃឈូងសមុទ្រអូម៉ង់។ មានហេតុផលសម្រាប់ការមិនចង់ និងការប្រុងប្រយ័ត្នរបស់ពួកគេ។ យ៉ាងហោចណាស់កប៉ាល់ចំនួន ១៨ គ្រឿងត្រូវបានវាយប្រហារ ហើយសមាជិកនាវិកយ៉ាងហោចណាស់ ៧ នាក់បានស្លាប់ យោងតាមអង្គការដឹកជញ្ជូនសមុទ្រអន្តរជាតិនៃអង្គការសហប្រជាជាតិ ដែលតាមដានសន្តិសុខសមុទ្រ។ អង្គការនេះមិនបានបញ្ជាក់ថាប្រទេសណាដែលបានវាយប្រហារកប៉ាល់ទាំងនោះទេ។ Lloyd’s List និយាយថាប្រាក់ឆ្លងកាត់ត្រូវបង់ជាអង្គរិចប្រាក់របស់ប្រទេសចិន «អង្គការ IRGC របស់អ៊ីរ៉ង់បានដាក់ពាក្យបញ្ជា "ប៉ុស្តិ៍ប្រាក់ឆ្លងកាត់" ជាការពិតនៅក្នុងច្រកសមុទ្រហរមូស» ក្រុមហ៊ុនផ្តល់ព័ត៌មានដឹកជញ្ជូនសមុទ្រ Lloyd’s List Intelligence និយាយថា។ ជាធម្មតាកប៉ាល់ប្រើប្រាស់ឆានែលដឹកជញ្ជូន ២ ផ្លូវនៅពាក់កណ្តាលច្រកសមុទ្រ។ ប៉ុន្តែកាន់តែច្រើនឡើងៗ កប៉ាល់កំពុងប្រើផ្លូវផ្សេង ទៅភាគខាងជើងជុំវិញកោះឡារ៉ាក ដែលធ្វើឱ្យពួកគេស្ថិតនៅក្នុងទឹកដីសមុទ្ររបស់អ៊ីរ៉ង់ និងកាន់តែខិតទៅជិតឆ្នេរសមុទ្រអ៊ីរ៉ង់។ អង្គភាពដែលចង់ឱ្យកប៉ាល់របស់ពួកគេឆ្លងកាត់ដោយសុវត្ថិភាពត្រូវតែដាក់បញ្ចូលព័ត៌មានលម្អិតរបស់ពួកគេទៅកាន់អ្វីដែល Lloyd’s List Intelligence ហៅថា "អ្នកការពារដែលបានអនុម័ត" នៃកងឆ្មាំបដិវត្តន៍ រួមទាំងទំនិញដឹក ម្ចាស់កប៉ាល់ ទិសដៅ និងបញ្ជីនាវិកពេញលេញ។ កប៉ាល់ដែលត្រូវបានអនុម័តនឹងទទួលបានកូដ ហើយត្រូវបានអមដោយកប៉ាល់របស់ IRGC។ ប្រេងត្រូវបានផ្តល់អាទិភាព ហើយកប៉ាល់ទាំងអស់ត្រូវស្ថិតនៅក្រោម "ការពិនិត្យភូមិសាស្ត្រនយោបាយ" Lloyd’s និយាយថា។ «ទោះបីជាមិនមែនកប៉ាល់ទាំងអស់សុទ្ធតែបង់ប្រាក់ឆ្លងកាត់ដោយផ្ទាល់ក៏ដោយ ក៏យ៉ាងហោចណាស់កប៉ាល់ចំនួន ២ គ្រឿងបានបង់ ហើយការទូទាត់ត្រូវបានធ្វើឡើងជាប្រាក់អង្គរិច» Lloyd’s List និយាយថា ដោយសំដៅទៅលើរូបិយប័ណ្ណរបស់ប្រទេសចិន។ កប៉ាល់មួយចំនួនហាក់ដូចជាត្រូវបានអនុញ្ញាតឱ្យឆ្លងកាត់បន្ទាប់ពីមានសម្ពាធការទូត។ កប៉ាល់ឥណ្ឌាចំនួន ២ គ្រឿងដឹកឧស្ម័នប្រេងរាវបានអាចឆ្លងកាត់បាន យោងតាម Lloyd’s។ អ៊ីរ៉ង់ហាក់ដូចជាកំពុងបង្កើតប្រព័ន្ធអចិន្ត្រៃយ៍ នៅថ្ងៃអង្គារនេះ អង្គការ IMO បានទទួលលិខិតពីរដ្ឋាភិបាលអ៊ីរ៉ង់ដែលនិយាយថាខ្លួន "បានអនុវត្តវិធានការប្រុងប្រយ័ត្នមួយចំនួនដែលមានគោលបំណងថែរក្សាសុវត្ថិភាព និងសន្តិសុខសមុទ្រ"។ លិខិតនេះបានអះអាងថាអ៊ីរ៉ង់កំពុងធ្វើសកម្មភាពក្រោមគោលការណ៍នៃច្បាប់អន្តរជាតិ។ សភាអ៊ីរ៉ង់ហាក់ដូចជាកំពុងដំណើរការសេចក្តីព្រាងច្បាប់ដើម្បីធ្វើឱ្យកម្រៃសម្រាប់កប៉ាល់មួយចំនួននៅក្នុងច្រកសមុទ្រហរមូសកាន់តែផ្លូវការ ប្រព័ន្ធផ្សព្វផ្សាយមូលដ្ឋានរាយការណ៍ថា។ ទីភ្នាក់ងារព័ត៌មាន Fars និង Tasnim ដែលទាំងពីរនាក់ជិតស្និទ្ធនឹងកងឆ្មាំបដិវត្តន៍អ៊ីរ៉ង់ បានដកស្រង់សម្តីរបស់សមាជិកសភា Mohammadreza Rezaei Kouchi ដែលនិយាយថា "សភាកំពុងអនុវត្តផែនការដើម្បីចងក្រងជាច្បាប់ផ្លូវការនូវអធិបតេយ្យភាព ការគ្រប់គ្រង និងការត្រួតពិនិត្យរបស់អ៊ីរ៉ង់លើច្រកសមុទ្រហរមូស ខណៈពេលដែលបង្កើតប្រភពប្រាក់ចំណូលផងដែរតាមរយៈការប្រមូលកម្រៃ"។ អង្គការ IMO បានថ្កោលទោសការវាយប្រហារលើកប៉ាល់ និងអំពាវនាវឱ្យមានវិធីសាស្រ្តសម្របសម្រួលអន្តរជាតិដើម្បីធានាសុវត្ថិភាពការឆ្លងកាត់តាមច្រកសមុទ្រនេះ ដោយគោរពសេរីភាពនៃការធ្វើដំណើរសមុទ្រ។ នាយកប្រតិបត្តិប្រេងនៃប្រទេសអេមីរ៉ាតអារ៉ាប់រួមហៅការក្តាប់ករបស់អ៊ីរ៉ង់ថាជា "អំពើភេរវកម្មសេដ្ឋកិច្ច" សម្តីរបស់ Sultan al-Jaber ដែលជាអ្នកដឹកនាំក្រុមហ៊ុនរដ្ឋ Abu Dhabi National Oil Co. ដ៏ធំសម្បើម បានបង្ហាញពីការកើនឡើងនៃសំលេងតឹងរឹងរបស់ប្រទេសអេមីរ៉ាតអារ៉ាប់រួម នៅពេលដែលសង្គ្រាមជិតដល់ខែទីមួយហើយ។ «ការប្រើច្រកសមុទ្រហរមូសជាអាវុធមិនមែនជាសកម្មភាពឈ្លានពានប្រឆាំងនឹងប្រទេសមួយទេ» al-Jaber និយាយនៅក្នុងសុន្ទរកថាសម្រាប់ព្រឹត្តិការណ៍ដែលរៀបចំដោយវិទ្យាស្ថានមជ្ឈិមបូព៌ានៅវ៉ាស៊ីនតោន។ «វាគឺជាអំពើភេរវកម្មសេដ្ឋកិច្ចប្រឆាំងនឹងអតិថិជនទាំងអស់ គ្រួសារទាំងអស់ដែលពឹងផ្អែកលើថាមពល និងម្ហូបអាហារដែលមានតម្លៃសមរម្យ។ នៅពេលដែលអ៊ីរ៉ង់កាន់ច្រកសមុទ្រហរមូសជាចំណាយ ប្រទេសទាំងអស់សុទ្ធតែបង់ប្រាក់លោះ នៅប៉ុស្តិ៍បូមប្រេង នៅហាងលក់សម្ភារៈបរិភោគ និងនៅឱសថស្ថាន» គាត់និយាយថា។ «មិនអាចអនុញ្ញាតឱ្យប្រទេសណាមួយធ្វើឱ្យសេដ្ឋកិច្ចពិភពលោកអស្ថិរភាពតាមរបៀបនេះបានទេ»។ វិធីសាស្រ្តរបស់អ៊ីរ៉ង់អាចរំលោភលើច្បាប់អន្តរជាតិ អត្ថបទនេះត្រូវបានផ្តល់ជូនដោយអ្នកផ្គត់ផ្គង់មាតិកាដែលទីបញ្ចូល។ SeaPRwire (https://www.seaprwire.com/) មិនមានការធានា ឬ បញ្ចេញកំណត់ណាមួយ។ ប្រភេទ: ព័ត៌មានប្រចាំថ្ងៃ, ព័ត៌មានសំខាន់ SeaPRwire ផ្តល់សេវាកម្មផ្សាយពាណិជ្ជកម្មសារព័ត៌មានសកលសម្រាប់ក្រុមហ៊ុន និងស្ថាប័ន ដែលមានការចូលដំណើរការនៅលើបណ្ដាញមេឌៀជាង 6,500 បណ្ដាញ ប័ណ្ណប្រតិភូ 86,000 និងអ្នកសារព័ត៌មានជាង 350 លាន។ SeaPRwire គាំទ្រការផ្សាយពាណិជ្ជកម្មជាសារព័ត៌មានជាភាសាអង់គ្លេស ជប៉ុន ហ្រ្វាំង គូរី ហ្វ្រេនច រ៉ុស អ៊ីនដូនេស៊ី ម៉ាឡេស៊ី វៀតណាម ចិន និងភាសាផ្សេងទៀត។

Playtech CEO targets global growth opportunities as company seeks to regain momentum

admin

(AsiaGameHub) -   Live casino products provide limitless opportunities for operators in the U.S., as stated by Mor Weizer, Chief Executive Officer of Playtech, during an interview with SBC News. Shortly after Playtech released its full-year 2025 results, Weizer told us that the Group will stay focused on expanding the live casino market in the U.S., even though the product has lower adoption rates than in many other global regions. “We see the U.S. as a huge opportunity,” he noted. “Live casinos are indeed very popular in Asia, and they’re also well-received in some other markets—there are countries where live casino makes up 25-30% of total gaming activity. “In the U.S., as you rightly noted, adoption rates are still limited to around 17%. However, we see this as a chance because we are confident that the U.S. market’s fundamentals will enable significant growth in live casino.  “As we stated earlier today, live casino customers generate 1.8 times more revenue than regular casino players, which creates a cross-selling opportunity for operators to expand live casino offerings in the U.S. further.” A Global Shield Against Tax Burdens The Americas region overall has been a critical contributor to Playtech’s financial performance over the past year, particularly as the company undergoes a rapid transition to a B2B-focused business. However, a notable point from the FY25 report was that B2B costs rose while B2B revenue declined year-over-year (YoY). When asked if Playtech can reverse this trend in 2026, Chris McGinnis, Chief Financial Officer, noted that revenue was affected by the updated agreement with Caliente International, but costs are projected to increase at a slower pace this year, and profits are expected to return to growth alongside this. Looking ahead, this year is set to bring higher tax burdens in several of Playtech’s key markets, including Brazil and the UK. Nevertheless, the company’s management is confident that Playtech can weather these challenges due to its diversified portfolio. McGinnis explained: “The most significant impact for Playtech has been in the UK, where the government announced an increase in the Remote Gaming Duty. We issued a statement indicating that this would have a major effect on our business.  “But we remain optimistic. Playtech is geographically diversified, so even with tax hikes in the UK and other regions, we are still confident that we will continue to grow.” Weizer further emphasized: “We have a strong presence in other markets such as Italy, Spain, France, Poland, Romania, and the Scandinavian region. This broad diversification means we are well-equipped to handle any regulatory changes that may arise.” Finally, Playtech confirmed that it is exploring several new markets to boost its diversification, specifically Finland, New Zealand, and Ireland. All three nations are currently implementing major regulatory changes.  Finland is working to end its state-run gambling monopoly with operator Veikkaus by June 2027, New Zealand is set to launch its first online gambling licenses, and Ireland has a new gambling regulator that will reshape the country’s domestic market. Weizer concluded: “Finland is adopting a new regulatory framework that will allow operators to enter the market openly. We view this as a chance to deepen our partnership with Veikkaus. “We also have existing Scandinavian partners who are eager to enter the Finnish market as soon as the regulatory changes take effect. “New Zealand, meanwhile, is currently unregulated but is considering introducing regulations. Playtech is seeking to partner with operators that are likely to establish themselves there, including both B2B partners and structured agreement partners. “As for Ireland, they are also revising their regulatory framework. We see this as an opportunity due to our strong connections with individuals who have access to the Irish market.” This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

BoscaSports, an Irish technology innovator, acquires 2DB, a leading video streaming and data solutions company.

admin

(AsiaGameHub) -   BoscaSports, the Irish technology firm revolutionizing live betting information for racecourses and betting operators globally, has finalized its acquisition of UK-based 2DB, an integrated video streaming and data solutions business specializing in digital display technology. This transaction positions the combined entity as a leading provider of LBO display technology, video streaming, and data-driven distribution services in the market. The acquisition received support through a loan facility from Allied Irish Bank (AIB), signifying strong confidence in BoscaSports’ performance, strategy, and long-term potential. Eugene Mitchell, CEO of BoscaSports, said: This acquisition is truly transformative for BoscaSports. Merging our strengths with 2DB’s integrated video streaming and data solutions greatly improves our technological foundation, broadens our distribution footprint, and boosts the value we can provide to racecourses, operators, and bettors globally. We are proud to represent an Irish tech success story and appreciate the backing from AIB and Racecourse Media Group (RMG) as we move into this next stage of expansion. RMG, a minority investor in BoscaSports since its inception, has increased its investment to facilitate the deal and ensure the company has ample resources for future innovation. Nick Mills, CEO of Racecourse Media Group, said: BoscaSports has been a dependable partner from the very start, and we are pleased to endorse this acquisition. Ensuring the durability of our investment and enabling BoscaSports to offer long-term, leading-edge solutions is vital for the entire racing industry and enhances shareholder value for our racecourses. 2DB is a UK-based software expert, delivering integrated video streaming and real-time data solutions that drive digital display systems throughout the gaming industry. The company is highly regarded by major international brands for its dependability, technical proficiency, and extensive experience. Steve Boffo, Managing Director of 2DB Ltd, said: We are thrilled to announce that 2DB has been acquired by BoscaSports. This represents an ideal cultural and strategic alignment, and we are prepared to move forward swiftly for the benefit of our team and our customers. The incorporation of 2DB will result in a doubling of BoscaSports’ team, allowing the company to speed up product development, broaden its international presence, and further improve video, data, and display solutions across on-course, retail, and online betting platforms. Pat Horgan, Head of Business Banking, Capital Markets, AIB, said: At AIB, we take pride in backing Ireland’s homegrown technology companies as they expand globally. Their innovation stimulates economic growth, generates high-value employment, and solidifies Ireland’s standing as a prominent global technology hub. Bosca Technologies perfectly illustrates this ambition, demonstrating how pioneering innovation, robust strategic alliances, and a global outlook can lead to success on the international stage. BoscaSports presently supplies live betting data to retail displays at all 86 racecourses throughout the UK and Ireland, and the Group will now extend its operations to 12 countries, including Italy, Sri Lanka, Cyprus, Malta, Morocco, and the UAE. The consolidated client roster in the UK and Ireland now encompasses leading operators like Flutter’s brands, such as Paddy Power, alongside Entain, Britbet, William Hill, Boyle Sports, UK Tote, Tote Ireland, and the independent sector. Furthermore, the company has secured several notable new contracts over the past year, involving Abu Dhabi Turf Club/Momentum, MST (Italy), SOREC in Morocco, Ascot Racecourse, and BetMakers/Greyhound Racing Ireland. BoscaSports’ revenue saw an approximate 40% increase in the last 12 months, highlighting the robustness of its technology and its lucrative, expandable business model. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

Sports Betting and Gaming Companies Expand Sponsorships Across Diverse Sports

admin

(AsiaGameHub) -   Despite ongoing discussions about marketing budget reductions, sports sponsorship activity within the global betting and gaming sector shows no signs of deceleration. The past fortnight has seen a new surge of agreements spanning motorsport, football, baseball and sports data. This Sponsor Spotlight examines the worldwide platform of Formula 1, explores various football agreements throughout Europe, and ventures across the Atlantic to identify which iGaming operators are establishing a presence in the US market and their specific locations. Allwyn races to the forefront of Formula 1 Following a successful inaugural season, Formula 1 has prolonged its collaboration with Allwyn via a new multi-year contract. The agreement capitalises on Formula 1's sustained international expansion, with the sport now reaching 827 million supporters and a total television viewership of 1.8 billion. The refreshed partnership prioritises enhancing fan interaction through digital and interactive initiatives. A significant enhancement involves Allwyn's incorporation into the F1 Predict platform, enabling fans to predict race results through the newly created "Allwyn League", with rewards including grand prix tickets and Paddock Club entry. The brand will also achieve greater exposure during formation laps, representing one of the most prominent segments of a race weekend. This development follows a momentous period for the UK's National Lottery operator, encompassing the release of its financial results, finalisation of its OPAP merger, and exceeding the £450 million investment threshold for National Lottery modernisation. Tipico scores in the nation of its headquarters Tipico Group has entered into a multi-year contract with the Malta Football Association, securing status as an official partner of the national squad. Departing from conventional sponsorship models, this arrangement focuses on employer brand development, specifically promoting Tipico's recruitment platform and drawing local expertise in technology, finance and business positions. The collaboration encompasses branding on team kits, stadium promotions and digital media, all designed to boost recognition among Malta's labour pool and reinforce Tipico's standing as a permanent employer in what has become a favoured location for iGaming companies. PureWager goes in to bat for Baltimore Orioles PureWager Group has entered the US professional sports arena via a sponsorship agreement with the Baltimore Orioles. This designation establishes PureWager as the sole sports betting partner of the baseball organisation and involves establishing the PureWager Pavilion at Oriole Park, Camden Yards, conceived as a communal area for supporters. The deal coincides with PureWager's preparations to debut its wagering and online casino platform in the United States, with intentions to expand into numerous states after an initial launch in Michigan. Eurobet.live taps into ‘second screen’ trend with AS Roma Eurobet.live has secured a multi-year sponsorship with AS Roma, assuming the role of the club's principal shirt sponsor until the 2028/29 campaign. The collaboration is notable for its emphasis on infotainment over conventional sportsbook marketing, seeking to comply with Italy's stringent advertising restrictions. Eurobet.live will assume a pivotal function in AS Roma's digital content approach, generating matchday material, interviews and social media elements. The agreement targets the "second screen" demographic – supporters who interact with statistics and content whilst viewing matches. Veikkaus sponsor capitalises on a Scandinavian niche Finnish National Lottery operator Veikkaus Oy has been appointed principal partner of this year's men's Floorball World Championships, hosted in Finland. Finland's men's team enters the competition as defending world champions, having secured the title in Sweden during 2024. The sport has surged in popularity throughout Scandinavia, with final weekend tickets already exhausted, as Veikkaus seeks to leverage this momentum through sponsorship and broaden brand recognition before significant industry reforms in Finland. Spotlight rankings: Who’s standing out? 1: Formula 1 / Allwyn Viewed globally, this partnership is particularly prominent. Combining Formula 1's extensive reach with Allwyn's expanding sporting footprint, it unites two substantial organisations on a worldwide platform. Both entities have also experienced recent international expansion. 2: PureWager / Baltimore Orioles Entering the US sports market via an MLB franchise provides PureWager with a robust foundation for establishing brand recognition before a broader rollout. 3: Eurobet.live / AS Roma Italy's wagering market ranks as Europe's second-largest, and the revised regulatory structure has been well received. Gaining exposure through a prominent Serie A club represents a shrewd strategic decision. 4: Tipico / MFA While Malta stands among the globe's most significant gambling centres, its domestic market remains relatively modest by European standards due to the country's limited population. Nevertheless, preserving positive relationships with local sporting partners is always advisable. 5: Veikkaus Oy / Floorball Finally, Veikkaus' most recent sponsorship initiative does not match the scope of other agreements examined here. Nonetheless, it aligns perfectly with the company's reputation as a socially conscious operator, potentially offering significant advantages when Finland liberalises its market to additional licensees in 2027. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

Xunce Technology’s Revenue Surges 449% Half-on-Half: Is a Structural Revaluation to a Hundred-Billion Market Cap Camp on the Horizon?

admin

HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - As AI accelerates into the inference era, enterprise-grade AI is achieving large-scale deployment, driving an exponential surge in Token consumption and ushering data demand into a new development stage. Against this backdrop, high-quality, structured and scenario-specific professional data has become critical for enterprises to forge core strategic competitiveness in the era of AI.As a leading provider of AI real-time data infrastructure and analysis services in China, Xunce Technology is rapidly solidifying its core position in AI data, driven by industry tailwinds, full-chain technological capabilities and diversified growth engines. Amid the unfolding landscape of the intelligent economy, this ten-year industry stalwart is entering a pivotal window for structural revaluation.Token Value Restructuring: Making Every Data Access Quantifiable and MonetizableFounded in 2016, Xunce Technology has built a full-chain technological system spanning data acquisition, cleansing, standardization, real-time computing and large- model optimization over a decade of development. With AI Data Agent at its core, the Company specializes in millisecond-level real-time data processing, serving a diversified portfolio of industries including finance, urban governance, high-end manufacturing, healthcare, robotics, satellite applications, low-altitude economy, electric power, power grids and energy.As the era of AI inference unfolds, Token is evolving from mere “fuel” to a form of “hard currency”. Maximizing the value of each individual Token has emerged as a central challenge in the large-model inference era. Today, general-purpose large models typically rely on a “computing power for precision” approach, where every inference run generates substantial wasteful Token consumption. Should inference fail, all Tokens expended in the process are lost entirely, which is a common pain-point plaguing general AI systems.By contrast, vertical AI solutions equip general large language models with an external industry “brain” powered by domain-specific data. At its core, such solutions optimize inference logic via business-aware models, enabling upfront task feasibility validation and eliminating Token waste at the source. With deep expertise in professional vertical domain data modeling, Xunce Technology leverages its extensive portfolio of high-quality, scenario-specific proprietary data to act as an “efficiency multiplier” for every Token invocation. This structure translates Token consumption into higher-precision outputs while securing maximal result certainty. Crucially, the Company is developing full-chain capabilities spanning data metering, pricing and settlement, enabling quantifiable and monetizable measurement for every data access. By elevating per-unit Token efficiency, it delivers enhanced business value to enterprise clients.Aligned with this strategy, Xunce’s platform features a “LEGO-inspired” modular architecture, enabling clients to flexibly compose modules tailored to their specific needs. This “assemble-on-demand, adapt-in-real-time” design fosters deep and long-term customer stickiness. The Company also employs a highly flexible pricing framework, with fees structured around module count, processing throughput and other key metrics. Supported by subscription, transaction-based and Token-based payment models, its pricing mechanism precisely aligns with diverse client demands.Currently, Xunce Technology is fully building a full-chain data measurement and settlement system. It is exploring pricing mechanisms tied to large model inference frequency and module usage count, allowing customers to pay for effective Tokens rather than raw computing power consumption.Inflection Point Reached, Profitability ConfirmedDriven by Token value restructuring and innovative business models, Xunce Technology has delivered robust performance and reached a historic inflection point. In H2 2025, the Company posted an adjusted net profit of RMB 50 million, achieving its first positive profitability. Meanwhile, revenue rose from RMB 197.85 million in H1 2025 to RMB 1,086.81 million in H2, representing a 449.32% quarter-on-quarter surge. Amid rapid business expansion, the Company has witnessed a substantial improvement in profitability.Explosive Revenue GrowthReturn to Profit in H2Doubled ARPU & Per Capita GrowthImproved Cash Flow & Operating Metrics+103% Y/YNarrowed by 33%+105% Y/YSignificant Improvement2025 full-year revenue YoY growth2025 full-year adjusted net loss2025 ARPU YoY growth2025 net operating cash flow+449% H/HRMB 50 million+135% Y/YAmple cash on hand in 20252025 H2 revenue HoH growth2025 H2 adjusted net profit2025 per capita revenue YoY growthAverage collection period decreased in 2025For the full year, the Company posted total operating revenue of RMB 1,284.66 million, representing a substantial year-on-year increase of 103.28% and successfully breaking the key milestone of RMB 1 billion in revenue. This signifies that the Company has evolved from an early-stage, technology-driven startup into a new era of platform-based development with scalable and replicable business models.Furthermore, the Company’s combined gross proceeds for 2025 amounted to approximately RMB 792.08 million, representing a substantial increase of 63.44% compared to approximately RMB  484.63 million in the previous year. In terms of adjusted net loss, after deducting one-off non-recurring gains and losses, the Company’s adjusted net loss for 2025 was RMB 54.84 million, representing a significant narrowing of 33% from RMB 82.37 million in 2024.Notably, the Company achieved combined gross margin of 62% in 2025, exceeding that of Cambricon (55%), a leading AI chip provider, and far outpacing general large- model developer Minimax (25.4%). This underscores its high-value strategic positioning and resilient business model in the AI data infrastructure sector.In terms of R&D investment, Xunce Technology has also maintained efficient growth conversion. In 2025, the Company’s R&D expenditure reached RMB 450.44 million, with R&D expenses accounting for 48% of revenue, driving a 105% year-on-year increase in operating revenue. For comparison, Minimax’s R&D expenditure accounted for as high as 219% of its revenue, with a revenue growth rate of 159%. Xunce achieved a comparable expansion pace with a lower R&D intensity.As revenue scale continues to expand and gross margin in new industries gradually stabilize, the Company’s short-term objective is to achieve an inflection point in adjusted net profit. Looking ahead, as the industries already deployed enter a period of margin stabilization and Token-based payment and revenue-sharing models gain accelerated traction, its net profit is poised to improve at an accelerated rate.Driven by Diversified Growth Engines, Business Structure Continuously OptimizedThe robust revenue growth is not accidental, but underpinned by Xunce Technology’s multi-dimensional, systematically structured growth framework.Accelerate cross-industry replication. The Company currently covers 9 major industries, benchmarking Palantir’s 17 industries and leaving ample room for horizontal expansion. Xunce Technology is rapidly deepening its presence in key national strategic sectors such as asset management, telecommunications, electric power, urban management, high-end manufacturing, healthcare, energy, robotics training platforms and commercial aerospace. For each new industry, the Company first completes industry-specific data accumulation over 3 to 5 years, enabling rapid replication and scaled deployment across peer customers thereafter.The business model fosters deep customer value enhancement. As customers evolve from single-module adoption to multi-module deployment, and from pilot trials to full integration into core business workflows, substantial upside potential in ARPU remains. By synergistically lifting Token invocation volume, module usage count and per-Token value, the Company will unlock a new dimension of growth.Steadily expand overseas business and establish a global layout. The Company targets raising its overseas revenue share to 10% to 15% in 2026, and will further escalate its globalization strategy during 2027 and 2028, unlocking new avenues for sustained long-term growth.Cultivate a strategic cooperative ecosystem to forge deep integration with upstream and downstream partners in computing power and algorithms. Xunce Technology is engaging in in-depth collaboration with leading domestic GPU providers and large language model enterprises to build a one-stop solution encompassing “infrastructure computing power, upper-layer applications and data governance,” further solidifying its core position in the AI data infrastructure sector.      Pioneer cutting-edge applications to seize commanding heights in future industries. From robotics data platforms to commercial aerospace, low-altitude economy and power grid systems, Xunce Technology has taken the lead in extending AI infrastructure to emerging sectors with stringent demands for real-time performance and operational reliability. Such mission-critical scenarios with ultra-high requirements for data timeliness and stability serve as a rigorous validation of the Company’s technological advantages. The Company will continue to ramp up R&D investment in frontier fields, refine its technical capabilities through high-end application scenarios and unlock new high-growth, high-value growth tracks for long-term development.Evolving from Data Services to Core AI Economy Infrastructure: Building Sustainable Competitive BarriersFrom a macro perspective, the artificial intelligence data sector is witnessing a profound convergence of five defining trends: a surge in demand for real-time, secure, high-quality data in the era of AI Agent; the rise of domain-specific models elevating professional data as a critical enabler for industry-wide intelligent upgrading; standardization of data interfaces driven by next-generation AI operating systems including Open Claw, positioning Xunce Technology as a core data Token provider; Token-based payment emerging as a new paradigm for the data element market; and the implementation of data asset capitalization policies, spurring a sharp rise in enterprises’ mandatory investment in data governance.At the intersection of these five pivotal trends, Xunce Technology has established a robust fundamental logic for sustained long-term growth. The Company has evolved beyond a traditional data infrastructure provider to become a critical “connector” and “enabler” linking large models, computing power and cloud vendors. By integrating upstream models, downstream computing power and horizontal collaboration with cloud vendors, the Company delivers irreplaceable data-centric value to its enterprise clients.The Company stresses that it shares a natural upstream-downstream synergy with general large-model providers, rather than a competitive dynamic. Analogous to the deep collaboration between GPU manufacturers and model developers, the value of Xunce Technology lies in a mutually reinforcing cycle: the wider the adoption of models by its clients, the greater the opportunity for the Company to deliver services and generate incremental value for clients.Notably, in contrast to niche market players offering only isolated modules such as data cleansing or computing engines, Xunce Technology’s core differentiation lies in its full-process coverage and outcome-driven accountability. The Company provides an end-to-end solution spanning data acquisition, cleansing, standardization, modeling, real-time computing and model tuning, ensuring that final data delivered to clients is clean, accurate, real-time and accessible for model invocation at millisecond latency. Furthermore, through deep integration into clients’ private clouds or on-premises environments, the Company acts as a dedicated data steward, fostering exceptional customer stickiness and forging robust, sustainable competitive barriers.Currently, the Company’s product portfolio and solutions feature more than 300 functional modules, covering a full spectrum of scenarios from data infrastructure to upper-layer analytics applications. In 2025, its active paid clients base reached 230, with an outstanding customer retention rate of 90%. ARPU increased substantially from RMB 2.72 million in 2024 to RMB 5.59 million in 2025, representing a year-on-year growth of over 103%.As algorithms become increasingly open-source and computing power tends toward standardization, what truly sets companies apart lies in data — particularly industry data that has undergone sophisticated governance and can effectively empower large models. Backed by a decade of deep industry expertise, Xunce Technology has established a substantial and sustainable competitive barrier in this domain.ConclusionFrom an early-stage private equity tool provider to a cross-industry AI data infrastructure builder, and from a module supplier to a Token-priced core platform, Xunce Technology has remained committed to unlocking data as a scarce, strategic resource that is freely circulable, readily callable and empowered to drive high-quality decision-making.Amid the rapid emergence of new intelligent economic paradigms, the Company stands at the threshold of a fundamental structural revaluation, with the potential to enter the RMB 100-billion market cap camp. It is a competitor to none, but an indispensable partner to all. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy

admin

TOKYO, Mar 27, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and MSD K.K. (Headquarters: Tokyo, Representative Director: Prashant Nikam, “MSD”), a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, announced today that an application for LENVIMA® (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, has been submitted in Japan for the additional dosage and administration in combination with WELIREG® (belzutifan), the first-in-class oral hypoxiainducible factor-2 alpha (HIF-2α) inhibitor from MSD, for the treatment of unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy.This application is based on the results of the Phase 3 LITESPARK-011 trial evaluating the dual regimen of LENVIMA plus WELIREG for the treatment of patients with advanced renal cell carcinoma (RCC) whose disease progressed on or after treatment with anti-programmed death receptor-1 (PD-1)/ programmed death-ligand 1 (PD-L1) therapy. The data from this trial were presented at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in February 2026. At a pre-specified interim analysis with a median follow-up of 29.0 months (range, 19.3-49.2), the LENVIMA plus WELIREG combination therapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS), one of the primary endpoints, reducing the risk of disease progression or death by 30% (HR=0.70 [95% CI, 0.59-0.84]; p=0.00007) compared to cabozantinib. The safety profile of this combination was consistent with those reported for each agent administered as monotherapy, and no new safety signals were identified.In 2022, approximately 435,000 people worldwide were newly diagnosed with kidney cancer, and about 156,000 people died from the disease. 1 In Japan, it is estimated that roughly 21,000 people were newly diagnosed and about 7,000 died in 2022.2 RCC accounts for approximately 85% of kidney cancers3, and the five-year survival rates for patients with stage III and IV RCC have been reported as 63%–78% and 27%–28%4, respectively, indicating that the disease still has a high unmet medical needs.LENVIMA is approved in combination with KEYTRUDA ® (pembrolizumab) in Japan for the first-line treatment of unresectable or metastatic RCC. WELIREG is approved in Japan for the treatment of unresectable or metastatic RCC that has progressed following cancer chemotherapy. Additionally, supplemental New Drug Applications (sNDA) for the LENVIMA and WELIREG combination therapy for the treatment of adult patients with advanced RCC with a clear cell component following a PD-1 or PDL1 inhibitor has been accepted by the U.S. Food and Drug Administration (FDA), with a PDUFA (Prescription Drug User Fee Act) target action date set for October 4, 2026.Eisai and MSD have been collaborating through the provision of information on LENVIMA in Japan since October 2018, and will work together to expedite the maximization of contribution to patients with cancer.About LENVIMA (lenvatinib)LENVIMA, discovered and developed by Eisai, is an orally available multiple receptor tyrosine kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). LENVIMA inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1- 4, the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. In syngeneic mouse tumor models, LENVIMA decreased tumor-associated macrophages, increased activated cytotoxic T cells, and demonstrated greater antitumor activity in combination with an anti-PD-1 monoclonal antibody compared to either treatment alone. LENVIMA has been approved for the indications below.Thyroid cancer- Indication as monotherapy(Approved mainly in Japan, the United States, Europe, China and Asia)Japan: Unresectable thyroid cancerThe United States: The treatment of patients with locally recurrent or metastatic, progressive, radioiodine-refractory differentiated thyroid cancer (DTC)Europe: The treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI)Hepatocellular carcinoma- Indication as monotherapy(Approved mainly in Japan, the United States, Europe, China and Asia)Japan: Unresectable hepatocellular carcinomaThe United States: The first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)Europe: The treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy- Indication in combination with KEYTRUDA (generic name: pembrolizumab) and transarterial chemoembolization (Approved in China)Thymic carcinoma- Indication as monotherapy (Approved in Japan)Japan: Unresectable thymic carcinomaRenal cell carcinoma (In Europe other than the United Kingdom, the agent was launched under the brand name Kisplyx®)- Indication in combination with everolimus(Approved mainly in the United States, Europe and Asia) The United States: The treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapyEurope: The treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF) targeted therapy- Indication in combination with KEYTRUDA(Approved mainly in Japan, the United States, Europe and Asia)Japan: Radically unresectable or metastatic renal cell carcinomaThe United States: The first-line treatment of adult patients with advanced renal cell carcinomaEurope: The first-line treatment of adult patients with advanced renal cell carcinomaEndometrial carcinoma- Indication in combination with KEYTRUDA(Approved mainly in Japan, the United States, Europe and Asia)Japan: Unresectable, advanced or recurrent endometrial carcinoma that progressed after cancer chemotherapyThe United States: The treatment of patients with advanced endometrial carcinoma that is pMMR or not microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiationEurope: The treatment of adult patients with advanced or recurrent endometrial carcinoma (EC) who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and are not candidates for curative surgery.About WELIREG (belzutifan)WELIREG, Merck & Co., Inc., Rahway, NJ, USA’s, known as MSD outside of the United States and Canada, first-in-class hypoxia-inducible factor 2 alpha (HIF-2α) inhibitor, is an orally administered small-molecule designed to reduce transcription and expression of HIF-2α target genes associated with cellular proliferation, angiogenesis and tumor growth. By inhibiting HIF-2α signaling, WELIREG aims to disrupt key pathways certain tumors may use to adapt to low-oxygen conditions, including those that help promote abnormal blood vessel formation and support tumor survival. WELIREG has demonstrated antitumor activity in certain von Hippel-Lindau (VHL) diseaseassociated tumors, renal cell carcinoma and in pheochromocytoma or paraganglioma. As part of a broader clinical program, Merck & Co., Inc., Rahway, NJ, USA continues to research WELIREG monotherapy and combination approaches for people with genitourinary, breast and gynecologic cancers across a range of treatment settings to further define where HIF-2α inhibition may provide clinical benefit and to better understand which patients are most likely to respond. WELIREG has been approved in Japan for the treatment of certain von Hippel–Lindau (VHL) disease–associated tumors, as well as for unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy.LITESPARK-011 ResultsData from LITESPARK-011 (ClinicalTrials.gov, NCT04586231) were presented at the ASCO GU Symposium held in February 2026. LITESPARK-011 is a randomized, open-label Phase 3 trial (ClinicalTrials.gov, NCT04586231) evaluating WELIREG in combination with LENVIMA compared to cabozantinib for the treatment of patients with advanced clear cell RCC that has progressed on or after anti-PD-1/L1 therapy. The dual primary endpoints are progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as assessed by blinded independent central review (BICR), and overall survival (OS). Secondary endpoints include objective response rate (ORR) per RECIST v1.1 as assessed by BICR, duration of response (DOR) per RECIST v1.1 as assessed by BICR, and safety. The trial enrolled 747 patients who were randomized to receive WELIREG (120 mg orally once daily) plus LENVIMA (20 mg orally once daily) or cabozantinib (60 mg orally once daily).At a pre-specified second interim analysis with a median follow-up of 29.0 months (range, 19.3- 49.2), WELIREG plus LENVIMA demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of PFS, reducing the risk of disease progression or death by 30% (HR=0.70 [95% CI, 0.59-0.84]; p=0.00007) compared to cabozantinib. For WELIREG plus LENVIMA, the median PFS was 14.8 months (95% CI, 11.2-16.6) versus 10.7 months (95% CI, 9.2-11.1) for cabozantinib. A trend toward improvement in overall survival (OS), the trial’s other primary endpoint, was also observed for WELIREG plus LENVIMA (HR=0.85 [95% CI, 0.68-1.05]; p=0.06075). The median OS was 34.9 months (95% CI, 27.5-NR) for WELIREG plus LENVIMA versus 27.6 months (95% CI, 24.0-31.4) for cabozantinib. The trial is continuing, and OS will be evaluated at a subsequent analysis per the clinical trial protocol. Regarding secondary endpoints, at the first interim analysis with a median follow-up of 19.6 months (range, 9.9-39.8), WELIREG plus LENVIMA met ORR, demonstrating a statistically significant improvement compared to cabozantinib. A confirmed ORR of 52.6% (95% CI, 47.3-57.7) was observed for WELIREG plus LENVIMA versus 39.6% (95% CI, 34.6-44.8) for cabozantinib. At the second interim analysis with a median follow-up of 29.0 months, the median DOR was 23.0 months (95% CI, 2.0-44.3+) for WELIREG plus LENVIMA versus 12.3 months (95% CI, 1.8+-35.9+) for cabozantinib. WELIREG plus LENVIMA was administered to 370 patients and cabozantinib was administered to 371 patients. Grade ≥3 treatment-related adverse events (TRAEs) occurred in 71.6% of patients receiving WELIREG plus LENVIMA versus 65.8% of patients receiving cabozantinib. Adverse events led to treatment discontinuation in 11.1% of patients receiving WELIREG plus LENVIMA and in 11.3% of patients receiving cabozantinib, respectively. Serious adverse events were observed in 51.6% of patients receiving WELIREG plus LENVIMA versus 43.9% of patients receiving cabozantinib, and AEs led to death in 5.4% of patients (two were treatment-related: thrombotic microangiopathy [n=1] and pneumonitis [n=1]) versus 3.2% (one was treatment-related: hemoptysis [n=1]) of patients, respectively.About the Eisai and Merck & Co., Inc., Rahway, NJ, USA Strategic CollaborationIn March 2018, Eisai and Merck & Co., Inc., Rahway, NJ, USA through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA. Under the agreement, the companies jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy, KEYTRUDA, and HIF-2α inhibitor, WELIREG.Eisai’s focus on cancerEisai acknowledges “Oncology” as one of its key strategic areas, and will continue to focus on the discovery and development of anti-cancer drugs within drug discovery domains including “microenvironment”, “protein integrity and homeostasis”, and “cell lineage and cell differentiation” under the Deep Human Biology Learning (DHBL) drug discovery and development organization. Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these domains, with the aim of contributing to the cure of cancers.6. About EisaiEisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept [also known as our human health care (hhc) Concept], we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, our continued commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), is demonstrated by our work on various activities together with global partners. For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), us.eisai.com (for U.S. headquarters: Eisai Inc.) or www.eisai.eu (for Europe, Middle East, Africa, Russia, Australia, and New Zealand headquarters: Eisai Europe Ltd.), and connect with us on X (U.S. and global), LinkedIn (for U.S. and EMEA) and Facebook (global).Merck & Co., Inc., Rahway, NJ, USA’s Focus on CancerEvery day, we follow the science as we work to discover innovations that can help patients, no matter what stage of cancer they have. As a leading oncology company, we are pursuing research where scientific opportunity and medical need converge, underpinned by our diverse pipeline of more than 25 novel mechanisms. With one of the largest clinical development programs across more than 30 tumor types, we strive to advance breakthrough science that will shape the future of oncology. By addressing barriers to clinical trial participation, screening and treatment, we work with urgency to reduce disparities and help ensure patients have access to high-quality cancer care. Our unwavering commitment is what will bring us closer to our goal of bringing life to more patients with cancer. For more information, visit https://www.merck.com/research/oncologyAbout MSDAt MSD (the name by which Merck & Co., Inc., Rahway, NJ, USA, is known outside of the United States and Canada), we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.co.jp and connect with us on Facebook, Twitter, and YouTube.Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, et al. (2024) Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.who.int/media/globocan/factsheets/cancers/29-kidney-fact-sheet.pdf, accessed 27 Mar 2026.Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, et al. (2024) Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer, Available from: https://gco.iarc.who.int/media/globocan/factsheets/populations/392-japan-fact-sheet.pdf, accessed 27 Mar 2026.National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. 2025; 2026 Version 1. Rose TL and Kim WY. Renal cell carcinoma: a review. JAMA. 2024 Sep 24;332(12):1001– 10.Media InquiriesEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120MSD K.K.Communications DivisionTatsuro MuraseTEL: +81 (0)70-8700-0112 Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Hitachi and MUFG Bank expand NextGen model to finance vehicles and charging infrastructure for decarbonized mobility

admin

TOKYO, Mar 27, 2026 - (JCN Newswire via SeaPRwire.com) - Hitachi, Ltd. (TSE: 6501, “Hitachi”) and MUFG Bank, Ltd. (“MUFG Bank”), a consolidated subsidiary of Mitsubishi UFJ Financial Group, Inc. (TYO: 8306, “MUFG”) today announced a new Memorandum of Understanding (MoU) to expand NextGen, their business co-creation model. Building on their collaboration launched in May 2024*1 and further developed as announced in May 2025*2 , NextGen combines Hitachi’s technology and operational expertise with MUFG’s financial capabilities to accelerate the transition to decarbonized mobility.*1 MUFG’s Business Co-Creation and Investment into UK Battery as a Service project by Hitachi ZeroCarbon May 2024*2 Hitachi ZeroCarbon and MUFG unite technology expertise with financial support to accelerate fleet electrification May 2025NextGen was initially validated through a UK pilot project with First Bus, where the parties collaborated via a special purpose vehicle (SPV) to support the procurement and operation of electrification assets under a Battery-as-a-Service model. This expanded MoU extends NextGen beyond battery-focused structures, enabling broader and more scalable deployment across additional markets outside the UK and across a wider range of asset classes. These include emobility assets such as electric vehicles and charging infrastructure, associated energy management systems, and potentially extending to energy hubs supporting industrial assets, power grids and data centers.Hitachi and MUFG Bank will also develop and scale SPV structures to finance decarbonized mobility assets for fleet and transport operators. This approach removes capital constraints and accelerates implementation, enabling operators to focus on their core transport services. From Hitachi’s side, the initiative is led by its Strategic SIB Business Unit, bringing together expertise from across Hitachi including Hitachi Energy, as ‘One Hitachi’. Hitachi will also provide managed services for asset performance and lifecycle optimization, supported by data-driven solutions from Hitachi ZeroCarbon. Through this initiative, Hitachi aims to further advance and streamline mobility and charging infrastructure operations by expanding HMAX by Hitachi, a suite of next-generation solutions that embodies Lumada 3.0, differentiated by deep domain knowledge and AI.Electrifying commercial transport at pace will require an unprecedented deployment of vehicles, charging and energy infrastructure - alongside innovative financing models to support it. Global investment in electrified transport reached around US$750 billion in 2024, making it the largest segment of the energy transition worldwide*3 - yet many fleet operators face limited access to capital and the operational complexity of transitioning at scale. Against this backdrop, Hitachi and MUFG Bank aim to expand NextGen as a repeatable model to accelerate implementation by combining structured asset financing with managed services and data-driven optimization.*3 Sources: BloombergNEF’s Energy transition Investment Trends 2025In demonstration of the expanded pipeline, Hitachi ZeroCarbon and MUFG Bank have also entered into an MoU with Boreal Norge AS and its subsidiary Boreal Buss AS, one of Norway’s primary transport operators, providing transport services across several counties and employing around 3,000 employees across its fleet, which includes over 850 buses and 35 ferries. The parties will explore how they can support Boreal’s transition planning, de-risk operations, optimize services and strengthen competitiveness as concessions evolve.Jun Taniguchi, Senior Vice President and Executive Officer, CEO of Strategic SIB Business Unit, at Hitachi, Ltd. said:“We are delighted to advance this partnership which combines Hitachi’s deep expertise in social infrastructure and digital technologies with MUFG Bank, Ltd.’s financial strength to accelerate the transition to a decarbonized society. By improving the performance of assets such as batteries and charging infrastructure through Hitachi’s digital services led by HMAX, we can truly help customers optimize the total cost of ownership. This partnership embodies our One Hitachi approach, leveraging our diverse capabilities across the Group to support our customers in achieving their net-zero ambitions.”Masakazu Osawa, Senior Managing Executive Officer Chief Executive, Japanese Corporate & Investment Banking Business Unit of MUFG Bank, Ltd., said:“Building on MUFG’s Business Co‑Creation and Investment approach, this collaboration with Hitachi aims to create value through strategic partnerships that improve society and the environment. For the global EV market, our focus is not only on strengthening Hitachi’s leading position in Battery as a Service, but also on fostering a holistic value chain — including second‑ life battery markets — that supports the acceleration of electric mobility and the achievement of 2050 net‑zero targets. Together with our partners, we are committed to co‑creating sustainable businesses that become a driving force for progress worldwide.”Nikolai Knudsmoen Utheim, Group CEO, Boreal Norge AS said:“Our priority has always been to deliver first-class transport services to our customers, whether that’s on the road, rail or over water. In exploring how we can unlock the power of electrified fleets, we can not only deliver more sustainable operations, but upgrade our infrastructure and thread technology across our entire business model for more efficient, smart transport and energy management.”About Hitachi, Ltd.Through its Social Innovation Business (SIB) that brings together IT, OT (Operational Technology) and products, Hitachi contributes to a harmonized society where the environment, wellbeing, and economic growth are in balance. Hitachi operates globally in four sectors – Digital Systems & Services, Energy, Mobility, and Connective Industries – and the Strategic SIB Business Unit for new growth businesses. With Lumada at its core, Hitachi generates value from integrating data, technology and domain knowledge to solve customer and social challenges. Revenues for FY2024 (ended March 31, 2025) totaled 9,783.3 billion yen, with 618 consolidated subsidiaries and approximately 280,000 employees worldwide. Visit us at www.hitachi.com.About MUFGMitsubishi UFJ Financial Group, Inc. (MUFG) is one of the world’s leading financial groups. Headquartered in Tokyo and with over 360 years of history, MUFG has a global network with approximately 2,000 locations in more than 40 countries. The Group has about 150,000 employees and offers services including commercial banking, trust banking, securities, credit cards, consumer finance, asset management, and leasing. The Group aims to “be the world’s most trusted financial group” through close collaboration among our operating companies and flexibly respond to all of the financial needs of our customers, serving society, and fostering shared and sustainable growth for a better world. MUFG’s shares trade on the Tokyo, Nagoya, and New York stock exchanges. For more information, visit https://www.mufg.jp/english.About BorealBoreal is a leading mobility provider, operating buses, fast ferries, passenger ferries and trams in Norway and Sweden. We remain firmly committed to our societal mission of encouraging more people to travel collectively. At the same time, we are more than public transport. As the only company operating buses, ferries, fast ferries, trams and tourism services, we deliver integrated mobility solutions and travel experiences. Although Boreal is a young company in name, its heritage extends back more than 150 years. The company has around 3,000 employees and is headquartered in Stavanger, Norway. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Analogue 2025 Annual Results Profit Attributable to Owners of the Company Increases 23.5% to HK$167.0 Million

admin

HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - Analogue Holdings Limited (“Analogue” or the “Company”, together with its subsidiaries, the “Group”) (stock code: 1977), a leading provider of electrical and mechanical (“E&M”) engineering solutions, and information and communications technology services for smart cities, today announced its annual results for the year ended 31 December 2025 (“the Year” or “FY2025”) with net profit growth, contracts-in-hand achieving another record high and order intake more than doubled, providing a solid business foundation for the coming three years and beyond.Financial Highlights- Profit attributable to owners of the Company increased 23.5% to HK$167.0 million.- Contracts-in-hand surged 61.8% to HK$17,878.7 million, hitting another record-high, made possible by a 113.7% increase in order intake to HK$12,913.6 million during the Year.- The intake of new maintenance contracts for housing programmes, environmental projects and lifts and escalators increased 51.4% to HK$1,669 million, reinforcing the recurring revenue stream.- The Group maintained a strong cash position, with bank balances and cash of HK$1,020.8 million and gearing ratio reduced to 10.1% for FY2025 from 26.2%.- The Board has resolved to pay a second interim dividend of HK2.9 cents per share. Total dividend for the year amounted to HK5.5 cents per share with 25.6% increment year-on-year.Chairman Dr Mak Kin Wah said, “The Year 2025 saw profound changes around the world, with challenges and yet also opportunities. Our Group has continued to stride forward: upholding what we commit by delivering the fundamentals well, striving for continuous improvement to make transformation actionable, investing in technology advancement and productivity, and bringing Hong Kong’s engineering excellence to the world. We are pleased to report that the Group achieved profit growth, secured a record level of contracts-in-hand, and continued to build on our international market presence. These accomplishments highlight our distinctive comprehensive capability across diverse business segments, our commitment to excellence, and our leadership in advanced engineering techniques.”“Supported by strong cashflow, we are in a strong position to take on additional work where appropriate and to seize high-value opportunities as they arise. We will continue to stay agile and focused on capturing opportunities across our broad portfolio, build on our competitive strengths through continuous improvement, and reinforce the use of innovative solutions that enhance quality, safety and performance. We remain steadfast in our commitment to our customers, recognising that this is fundamental to earning their trust and cultivating enduring, strategic partnerships. Guided by our motto – ‘We Commit. We Perform. We Deliver’ – we will continue to maximise value for customers, shareholders, suppliers and stakeholders, while contributing to the communities we serve.”Business Review: Building Services- This segment remains the largest revenue contributor, with revenue reaching HK$3,279 million.- Contracts-in-hand reached a record-high level of HK$8,297 million with the total value of new contracts secured in FY2025 doubled to HK$6,470 million. The Group’s competitive edge in multidisciplinary packaged projects and its industry leadership in innovative MiMEP and other new engineering techniques helped it to secure major contracts.- With strategic investments to accelerate innovation and modern manufacturing facilities in Zhuhai and Hong Kong, the Group continues to lead in MiMEP and DfMA technologies.- Following the successful acquisition of a property management licence, the Group expanded its business to deliver integrated solutions across the entire building lifecycle. This new capability, spanning construction, maintenance, operations and long-term facility management, creates a potential revenue stream that complements core services.- Through continuous development of innovative technologies and operational optimisation, the segment is positioning itself to maintain the market competitiveness while exploring opportunities in other markets in Southeast Asia.Environmental Engineering- This segment achieved record-high contracts-in-hand and order intake, increasing 86.9% and 253.7% to HK$8,094 million and HK$5,355 million respectively. Segment revenue also increased by 18.0% year-on-year to HK$1,591 million.- The segment maintained active tendering throughout the period and was awarded significant contracts, including contracts of a record-breaking value to relocate sewage treatment works in Sha Tin to caverns, sewage pumping station at Ma On Shan and more.- Formed a joint venture company in Qingyang city to explore the operation and maintenance business in the Chinese Mainland.- Explored project opportunities in Asia and the Middle East and the expansion of its expert services into Europe.Information, Communications and Building Technologies (“ICBT”)- Segment revenue remained at HK$630 million. Contracts-in-hand totalled HK$852 million at the year end, and order intake was HK$523 million during the Year.- This segment continued to reinforce its leadership in green and intelligent building solutions under the DigiFusion brand, to enable the development of smarter, more sustainable urban environments.- Continued to leverage ATAL Tower as a platform for developing innovative technologies and broaden its technological capabilities through strategic collaborations with leading manufacturers in the Chinese Mainland and around the world, to strengthen its ability to deliver scalable, high-performance solutions across a wide range of sectors.Lifts and Escalators- Revenue and order intake increased 11.0% to HK$587 million and by 3.2% to HK$566 million respectively.- Transel Elevator & Electric Inc. (TEI), the associate company in the United States (US), secured a contract for the world-class vertical transportation system in the iconic 56-storey luxury hotel skyscraper on the border of Times Square in New York. TEI also further strengthened its market position by extending its footprint into the Southeastern part of US.- Actively built on its presence in the UK and broadened its network across other international markets, reinforcing its global ambitions in vertical transportation solutions.- Machine-Room-Less lift products continued to gain traction in key international markets- Streamlined the manufacturing processes of Nanjing factory, broadened its product portfolio and strengthened the overall product quality, aligning with the Group’s global vision and reaffirming its commitment to delivering reliable, high-performance vertical transportation solutions.For further details of the 2025 Annual Results, please refer to the announcement filed with The Stock Exchange of Hong Kong Limited.About Analogue Holdings LimitedEstablished in 1977, Analogue Holdings Limited is a leading provider of electrical and mechanical (“E&M”) engineering solutions and information and communications technology (“ICT”) services for smart cities, with headquarters in Hong Kong and operations in the Chinese Mainland, Macau, the United States, the United Kingdom, Germany, Singapore and Malaysia. Serving a wide spectrum of customers from public and private sectors, the Group provides multidisciplinary and comprehensive E&M engineering and technology services in four major segments, including Building Services, Environmental Engineering, Information, Communications and Building Technologies (“ICBT”) and Lifts & Escalators.The Group also manufactures and sells lifts and escalators internationally and has entered into an alliance with Transel Elevator & Electric Inc. (“TEI”), one of the largest independent lifts and escalators companies in New York, the United States. The Group’s associate partner, Nanjing Canatal Data-Centre Environmental Tech Co., Ltd. (603912.SS), specialises in manufacturing of precision air conditioners. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ប្រធានប្រតិបត្តិ Cursor ព្រមានថា ការសរសេរកូដតាមវិបវិហារ (vibe coding) បង្កើត “មូលដ្ឋានគ្រឹះមិនរឹងមាំ” ហើយទីបំផុត “អ្វីៗនឹងចាប់ផ្ដើមខ្ទេចខ្ទី”

admin

(SeaPRwire) -   ក្រុមហ៊ុន Cursor អាចប្រើប្រាស់ AI ដើម្បីជួយអ្នកសរសេរកូដក្នុងការសរសេរកូដ ប៉ុន្តែកុំហៅវាថា vibe coding ដែលបាននិយាយដោយ Michael Truell នាយកប្រតិបត្តិនិងសហប្រកបអាជីវកម្ម។ កាលពីដប់ឆ្នាំមុន ការសរសេរកូដមានន័យថាការវាយបញ្ចូលកូដទៅក្នុងកម្មវិធីសរសេរអត្ថបទទទេ និងកែសម្រួលដោយដៃ។ ប៉ុន្តែជាមួយនឹងការមកដល់នៃ AI បង្កើត ទម្រង់នៃការសរសេរកូដនេះកំពុងតែបាត់បង់ជាបន្ទាប់មកយ៉ាងឆាប់រហ័ស គាត់បានពន្យល់។ “កាន់តែច្រើនទៅទៀត អ្នកអាចថយក្រោយពីកូដហើយអ្នកអាចស្នើសុំ AI ធ្វើការងារពេញលេញសម្រាប់អ្នក។” Truell បាននិយាយនៅក្នុងសន្និសីទ Brainstorm AI ក្នុងខែធ្នូ។ ទោះយ៉ាងណាអ្នកសរសេរកូដប្រហែលជាមិនចង់ថយក្រោយច្រើនពេក គាត់បានបន្ថែម ដោយចង្អុលបង្ហាញថាមានកម្រិតនានាក្នុងការសរសេរកូដជួយដោយ AI។ តើ vibe coding គឺជាអ្វី? ពាក្យ “vibe coding” ដែលត្រូវបាននិយាយជាញឹកញាប់ហាក់ដូចជាអាចពិពណ៌នាអំពីកម្មវិធីជួយសរសេរកូដដោយ AI ទាំងអស់។ នៅក្នុងសេចក្តីពិត វាបង្ហាញពីអ្នកបង្កើតស្មុគស្មាញ ឬអ្នកប្រើ AI ដែលមិនមានបទពិសោធន៍ព្យាយាមធ្វើឱ្យគំនិតមួយក្លាយជាការពិតដោយមិនចាំបាច់ពិនិត្យមើលក្រោម។ “Vibe coding សំដៅទៅលើវិធីសាស្រ្តសរសេរកូដជាមួយ AI ដែលអ្នកបិទភ្នែកហើយមិនមើលកូដទាល់តែសោះ ហើយគ្រាន់តែស្នើសុំ AI បង្កើតវត្ថុសម្រាប់អ្នក។” គាត់បាននិយាយ។ Truell បានប្រៀបធៀបវាទៅនឹងការសាងសង់ផ្ទះដោយដាក់ជញ្ជាំងបួននិងដំបូល ដោយមិនដឹងអ្វីដែលកំពុងកើតឡើងនៅក្រោមឥដ្ឋឬខ្សែភ្លើង។ វិធីសាស្រ្តសរសេរកូដនេះប្រហែលជាកំពូលសម្រាប់អ្នកប្រើ AI ដែលចង់បង្កើតហ្គេមឬគេហទំព័រយ៉ាងឆាប់រហ័ស ប៉ុន្តែនៅពេលដែលនិយាយពីការសរសេរកូដកម្រិតខ្ពស់ អ្វីៗអាចចុះខ្សោយគាត់បានព្រមាន។ “ប្រសិនបើអ្នកបិទភ្នែកហើយមិនមើលកូដហើយអ្នកមាន AI បង្កើតអ្វីៗដោយមានមូលដ្ឋានមិនមั่នត្រជាក់ នៅពេលអ្នកបន្ថែមជាន់មួយទៀត ជាន់មួយទៀត ជាន់មួយទៀត និងជាន់មួយទៀត អ្វីៗនឹងចាប់ផ្តើមរលួយ។” គាត់បាននិយាយ។ របៀបដែល Cursor ខុសគ្នា—ហើយហេតុអ្វីវាសំខាន់ ជាមួយនឹង Cursor ផ្ទុយទៅវិញ អ្នកសរសេរកូដអាចបញ្ចូល AI ឲ្យដាច់ខាតទៅក្នុងបរិយាកាសអភិវឌ្ឍសារព័ត៌មានដែលអ្នកសរសេរកូដសរសេរកូដ។ ដោយប្រើបរិបទនៃកូដដែលមានស្រាប់ ឬសូម្បីតែមូលដ្ឋានកូដទាំងមូល វាអាចទាយបន្ទាត់បន្ទាប់ជាញឹកញាប់។ ឧបករណ៍នេះរួមបញ្ចូលអ្វីៗពីការបំពេញបន្ទាត់ច្រើនបន្ទាត់រហូតដល់ការបង្កើតមុខងារពេញលេញ។ វាក៏អាចជួយអ្នកសរសេរកូដធ្វើការរកបញ្ហានិងពន្យល់ពីកំហុសផងដែរ។ ទោះបីជាគាត់មានអាយុតែ២៥ឆ្នាំក៏ដោយ មតិរបស់ Truell អំពីការសរសេរកូដដោយ AI មានទំហំធំ។ គាត់និងអនុញ្ញាតិបរិញ្ញាបត្របីនាក់ទៀតម មកពីមហាវិទ្យាល័យ Massachusetts Institute of Technology បានបង្កើតអ្វីដែលនឹងក្លាយជា Cursor ក្នុងនាមជាគម្រោងក្នុងឆ្នាំ២០២២។ ចាប់តាំងពីពេលនោះ មានការរាយការណ៍របស់ Bloomberg ថា Cursor បានក្លាយជាកម្មវិធីជួយសរសេរកូដដែលពេញនិយមជាងគេ ដោយមានអ្នកប្រើប្រាស់ប្រចាំថ្ងៃច្រើនជាង១លាននាក់នៅឆ្នាំមុន។ យោងតាម CNBC ចាប់តាំងពីការចាប់ផ្តើមដំណើរការ ក្រុមហ៊ុនបានឈានដល់ប្រាក់ចំណូលប្រចាំឆ្នាំ១ពាន់លានដុល្លារ និងប្រមូលផ្តុំបុគ្គលិក៣០០នាក់។ Cursor បានទទួលការវិនិយោគដំបូងចំនួន២០លានដុល្លារពីមូលនិធិស្ថាបនិករបស់ OpenAI ក្នុងឆ្នាំ២០២៣។ ក្រោយមកវាបានរៃអង្គប្រាក់ច្រើនលានទៀតពីវិនិយោគិនកប់រហូតដែលធំបំផុតនៅ Silicon Valley រួមទាំង Andreessen Horowitz។ ក្នុងឆ្នាំ២០២៥ ក្រុមហ៊ុនបានបិទការរៃអង្គប្រាក់ចំនួន២,៣ពាន់លានដុល្លារក្នុងតម្លៃក្រុមហ៊ុនបន្ទាប់ពីការវិនិយោគ២៩,៣ពាន់លានដុល្លារ។ ទីបំផុត នៅខែនេះ Bloomberg បានរាយការណ៍ថាក្រុមហ៊ុនកំពុងស្ថិតក្នុងដំណើរការនៃការរៃអង្គប្រាក់ដែលនឹងកំណត់តម្លៃក្រុមហ៊ុនប្រហែល៥០ពាន់លានដុល្លារ។ בעודអ្នកសរសេរកូដ vibe អាចហោះហើរដោយមិនឃើញ លោក Truell បាននិយាយថាកម្មវិធីជួយសរសេរកូដរបស់ Cursor គឺជាកម្រិតល្អបំផុតនៃទាំងពីរ ដោយជួយអតិថិជនជំនាញរបស់វាប въងស្រួតទៅក្នុងព័ត៌មានលម្អិតនៃកូដរបស់ពួកគេ។ “ប៉ុន្តែនៅកន្លែងដែលអ្នកចង់ថយក្រោយហើយចង់ស្នើសុំ AI ធ្វើការផ្ទេរ១០០% អ្នកក៏អាចធ្វើបានដែរ។” គាត់បាននិយាយ។ កំណែនៃរឿងនេះត្រូវបានបោះពុម្ពផ្សាយដំបូងនៅលើ .com កាលពីថ្ងៃ២៥ ខែធ្នូ ឆ្នាំ២០២៥។ ព័ត៌មានបន្ថែមអំពី AI: លោក Trump បានជ្រើសរើស Zuckerberg, Huang, Ellison ឲ្យចូលក្រុមប្រឹក្សាបច្ចេកវិទ្យា—ប៉ុន្តែបដិសេធមusk និង Altman។ ផ្លូវ Wall Street មានជំនឿជាក់លាក់ថា AI នឹងឃាតកម្មវិធី SaaS។ ប្រវត្តិសាស្រ្តនិងសេដ្ឋកិច្ចនិយាយអ្វីផ្សេងទៀត។ ចំណុចប្រសព្វរបស់ Cursor: ការកើនឡើងយ៉ាងឆាប់រហ័ស និងអនាគតមិនប្រាកដប្រជែងនៃក្រុមហ៊ុនស្ថាបនិក AI ដែលមានតម្លៃ៣០ពាន់លានដុល្លារ។ អត្ថបទនេះត្រូវបានផ្តល់ជូនដោយអ្នកផ្គត់ផ្គង់មាតិកាដែលទីបញ្ចូល។ SeaPRwire (https://www.seaprwire.com/) មិនមានការធានា ឬ បញ្ចេញកំណត់ណាមួយ។ ប្រភេទ: ព័ត៌មានប្រចាំថ្ងៃ, ព័ត៌មានសំខាន់ SeaPRwire ផ្តល់សេវាកម្មផ្សាយពាណិជ្ជកម្មសារព័ត៌មានសកលសម្រាប់ក្រុមហ៊ុន និងស្ថាប័ន ដែលមានការចូលដំណើរការនៅលើបណ្ដាញមេឌៀជាង 6,500 បណ្ដាញ ប័ណ្ណប្រតិភូ 86,000 និងអ្នកសារព័ត៌មានជាង 350 លាន។ SeaPRwire គាំទ្រការផ្សាយពាណិជ្ជកម្មជាសារព័ត៌មានជាភាសាអង់គ្លេស ជប៉ុន ហ្រ្វាំង គូរី ហ្វ្រេនច រ៉ុស អ៊ីនដូនេស៊ី ម៉ាឡេស៊ី វៀតណាម ចិន និងភាសាផ្សេងទៀត។

Helen Bryce Appointed BHA’s Legal Counsel for UK Racing

admin

(AsiaGameHub) -   The British Horseracing Authority (BHA) has announced the appointment of Helen Bryce as its new General Counsel and Company Secretary, effective from 1 August 2026. This appointment is part of a significant restructuring of the governing body's leadership during a crucial time for UK racing. Bryce will oversee all legal, compliance, risk management, and corporate governance operations, providing counsel to both the Executive and the Board on legal and statutory duties. Her promotion signifies an internal progression, as she joined the BHA in 2017 and currently holds the position of Head of Legal and Governance. Before her tenure at the BHA, Bryce spent ten years at Bird & Bird, where she served as a senior associate in their technology, media, and sport division, developing expertise in intricate regulatory and commercial matters. She succeeds Catherine Beloff, who is leaving the organisation after more than a decade. During her time, Beloff managed two major governance reviews and established an independent judicial panel, contributing to the modernisation of the BHA’s regulatory framework. Bryce expressed that it is a "huge privilege" to join the BHA at a pivotal moment for UK racing. She stated, "The BHA has a critical role to play in safeguarding the integrity and future of British racing. Maintaining the highest standards of corporate governance, legal compliance and transparency is fundamental to that mission. “I look forward to working closely with colleagues and stakeholders across the industry to ensure that our policies and procedures not only meet regulatory expectations but also reinforce trust and accountability across the sport.” BHA heads to negotiation table Her appointment occurs amidst broader executive changes within the BHA. In March, Brant Dunshea officially took on the permanent role of CEO, having previously led the organisation on an interim basis following Julie Harrington's resignation in 2025. Concurrently, the BHA is continuing its search for a new Chair, following the unexpected departure of Lord Charles Allen in February. His six-year term concluded amidst reported disagreements with stakeholders and racing bodies regarding governance direction. The selection of a new Chair is considered vital. The BHA is preparing to enter negotiations with the Department for Culture, Media and Sport (DCMS) and bookmakers, represented by the Betting & Gaming Council (BGC), concerning the future funding model for the horseracing levy. The redesign of the levy was notably excluded from the scope of the UK Gambling Review, a decision that has escalated tensions with bookmakers, some of whom have indicated they might withdraw from racing if terms are unfavourable. Against this backdrop, Bryce's appointment is viewed as a move to bolster the BHA's legal and governance capabilities in anticipation of complex regulatory discussions. Prominent figures, including Matt Hancock, Ben Wallace, and HR veteran Julia Tyson, have already been mentioned as potential candidates for the vacant Chair position. Commenting on the appointment, Dunshea remarked, “Helen has made a valuable contribution to the BHA and to British racing over a sustained period, demonstrating not only astute legal judgement but also a deep understanding of the governance challenges facing modern sport.  “At a time when the BHA must engage in complex discussions on funding, regulation and long-term sustainability, her expertise will be central to ensuring that we meet our statutory responsibilities while maintaining the confidence of participants, stakeholders and the public.” He further added, “Her leadership will be instrumental as we navigate a period of structural change for racing, ensuring that our regulatory framework remains robust, transparent and fit for purpose.” This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

Brazil Targets Doubled Tax Revenue from Online Gambling

admin

(AsiaGameHub) -   Brazil’s tax authority, the Receita Federal (RF), projects a substantial increase in tax revenue from licensed online gambling by 2026. This projection comes after a reported 235% surge in taxes collected in Q1 2026 from the 87 active licenses within the Brazil Bets market, according to SBC Noticias Brazil. The federal government collected R$2.5bn (£350m) in taxes related to betting between January and February, a significant rise from the R$756m (£108.4m) gathered in the corresponding period of 2025. January alone contributed R$1.49bn, with February yielding R$1.04bn. Analysts have suggested a possible seasonal dip in February, potentially linked to the Carnival festivities. This sharp increase is attributed to the ongoing maturation of Brazil's regulated betting framework, which is now in its second year of full operation under Law No. 14,790/2023. Market growth has been a primary factor, with the number of fully licensed operators growing from 49 at the start of 2025 to 87 by February 2026, leading to improved channelization and tax collection. New fiscal measures were approved by Congress at the end of 2025 through Law No. 224/2025, introducing a gradual increase in the Gross Gaming Revenue (GGR) tax. The rate is set to rise from 12% to 13% in 2026, with a goal of reaching 15% by 2028. According to RF Secretary Robinson Barreirinhas, the initial phase of this incremental adjustment is anticipated to generate an additional R$260m in tax revenue solely in 2026, bolstering the government's confidence in betting as a reliable source of fiscal income. Based on current trends, the RF estimates that tax income from betting could range between R$11bn and R$13bn by the close of 2026, provided that sustained player demand supports the incremental tax increases. This represents a steady year-on-year growth from the R$9.95bn collected in 2025, rather than an exponential leap. Fuel to political fires For policymakers, this trend highlights a broader objective: to strike a balance between revenue generation and regulatory oversight as Brazil continues to refine its gambling framework amidst political discussions regarding the social implications of gambling. The Brazil Bets market is also undergoing several governance changes as it enters the spring season. In March, the PT government appointed Dario Durigan as the new Secretary of the Ministry of Finance and the Economy, following Fernando Haddad's acceptance of the PT Party's nomination to run for governor of the State of São Paulo. Concurrently, Daniele Cardoso has been confirmed as the new Secretary of the Secretariat of Prizes and Bets (SPA), the federal body responsible for regulating Brazil’s betting market, concluding months of industry speculation. Collectively, the fiscal growth and the institutional changes signify a market transitioning rapidly from its launch phase to policy consolidation, as Brazil Bets continues to develop under increased political and regulatory scrutiny. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

admin

TOKYO and NEW YORK, NY., Mar 27, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”), a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, and Nuvation Bio Inc. (NYSE: NUVB, Corporate Headquarters: New York, NY, CEO: David Hung, M.D., “Nuvation Bio”), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) for taletrectinib for the treatment of advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). The filing will follow a standard review timeline.Taletrectinib (marketed as IBTROZI® in the U.S. and Japan) is a highly selective, next-generation oral treatment for patients living with advanced ROS1+ NSCLC.1 In January 2026, Eisai and Nuvation Bio announced they had entered into an exclusive licensing and collaboration agreement in Europe and additional countries* outside the U.S., China and Japan to extend the global reach of taletrectinib. Following this filing to the EMA, additional filings are planned for the U.K., Canada and other regions included in Eisai’s licensed territories.Across Europe, nearly 400,000 people are diagnosed with lung cancer each year with NSCLC accounting for 80% of cases.2,3 It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease.4,5“The validation of the MAA is a significant moment for patients in Europe with ROS1+ NSCLC,” said Terushige Iike, Chief Business Officer of Eisai Co., Ltd. “With its efficacy and safety profile, we believe taletrectinib has the potential to become a standard of care therapy for the thousands of patients living with this aggressive disease in Europe. We look forward to working closely with the EMA during the review process with the goal of making this treatment available to appropriate patients who urgently need targeted options.”The application is based on data from the two pivotal Phase 2 clinical studies, TRUST-I and TRUST-II, evaluating taletrectinib in patients globally.6,7 Results from a pooled analysis of the TRUST clinical program were published in the Journal of Clinical Oncology in April 20258, and Nuvation Bio anticipates near-term disclosure of updated data reflecting even longer patient follow-up, further building on the depth and durability of responses observed to date. Additionally, given the comprehensive nature of the taletrectinib clinical dataset and based on favorable feedback received at a pre-submission meeting with the CHMP Rapporteur and Co-Rapporteur, the accepted MAA will be considered to support full approval.“Having seen the meaningful impact taletrectinib has already made for patients with ROS1+ NSCLC in the U.S., China and Japan, we are thrilled to partner with Eisai and have an accepted MAA for review in Europe,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “This accepted filing represents an important milestone in our global development strategy and brings us one step closer to delivering this highly selective, next-generation oral therapy to more patients who need it in Europe and around the world.”In June 2025, the U.S. Food and Drug Administration (FDA) granted full approval to taletrectinib for the treatment of locally advanced or metastatic ROS1+ NSCLC across lines of therapy, following a Priority Review and double Breakthrough Therapy designations. Taletrectinib is also approved for patients with advanced ROS1+ NSCLC in Japan, where it is marketed by Nippon Kayaku, and in China, where it is marketed by Innovent Biologics under the brand name DOVBLERON®.* Eisai’s licensed territories: Europe, the Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand, Singapore, the Philippines, Indonesia, Thailand, Malaysia, Vietnam and IndiaAbout ROS1+ NSCLCEach year, more than one million people globally are diagnosed with non-small cell lung cancer (NSCLC), the most common form of lung cancer.9 It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease.4,5 About 35% of patients newly diagnosed with metastatic ROS1+ NSCLC have tumors that have spread to their brain.10 The brain is also the most common site of disease progression, with about 50% of previously treated patients developing central nervous system (CNS) metastases.10,11About TaletrectinibTaletrectinib is an oral, potent, CNS-active, selective, next-generation ROS1 inhibitor therapy. On June 11, 2025, following Priority Review and Breakthrough Therapy designations for both TKI-naive and TKI-pretreated disease, the U.S. Food and Drug Administration (FDA) approved taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC. Learn more about taletrectinib in the U.S. at IBTROZI.com. 1About the TRUST Clinical ProgramThe TRUST clinical program comprises three registrational studies evaluating the safety and efficacy of taletrectinib. TRUST-I (NCT04395677) and TRUST-II (NCT04919811) are Phase 2 single-arm studies evaluating taletrectinib for the treatment of adults with advanced ROS1+ NSCLC in China (N=173) and globally (N=189), respectively. The primary endpoint of both studies is confirmed objective response rate (cORR) as assessed by an independent review committee. TRUST-IV (NCT07154706) is a Phase 3 placebo-controlled study evaluating taletrectinib for the adjuvant treatment of adults with resected early-stage ROS1+ NSCLC. The study will enroll approximately 180 patients in the U.S., Canada, Europe, Japan and China. The primary endpoint is disease-free survival as determined by investigator, and the primary completion date is estimated to be in 2030. Nuvation Bio is also sponsoring TRUST-III (NCT06564324), a confirmatory randomized Phase 3 study evaluating taletrectinib versus crizotinib in 138 patients in China with advanced ROS1+ NSCLC who have not previously received ROS1 TKIs.6,7About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe.About Nuvation BioNuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients’ lives. Our diverse pipeline includes taletrectinib (IBTROZI®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program.Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit www.nuvationbio.com or follow the company on LinkedIn and X (@nuvationbioinc).U.S. IndicationIBTROZI is indicated for the treatment of adult patients with locally advanced or metastatic ROS1+ nonsmall cell lung cancer (NSCLC).IMPORTANT SAFETY INFORMATION FOR IBTROZI® (taletrectinib)1WARNINGS AND PRECAUTIONSHepatotoxicity: Hepatotoxicity, including drug-induced liver injury and fatal adverse reactions, can occur. 88% of patients experienced increased AST, including 10% Grade 3/4. 85% of patients experienced increased ALT, including 13% Grade 3/4. Fatal liver events occurred in 0.6% of patients. Median time to first onset of AST or ALT elevation was 15 days (range: 3 days to 20.8 months).Increased AST or ALT each led to dose interruption in 7% of patients and dose reduction in 5% and 9% of patients, respectively. Permanent discontinuation was caused by increased AST, ALT, or bilirubin each in 0.3% and by hepatotoxicity in 0.6% of patients.Concurrent elevations in AST or ALT ≥3 times the ULN and total bilirubin ≥2 times the ULN, with normal alkaline phosphatase, occurred in 0.6% of patients.Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life-threatening, or fatal ILD or pneumonitis can occur. ILD/pneumonitis occurred in 2.3% of patients, including 1.1% Grade 3/4. One fatal ILD case occurred at the 400 mg daily dose. Median time to first onset of ILD/pneumonitis was 3.8 months (range: 12 days to 11.8 months).ILD/pneumonitis led to dose interruption in 1.1% of patients, dose reduction in 0.6% of patients, and permanent discontinuation in 0.6% of patients.QTc Interval Prolongation: QTc interval prolongation can occur, which can increase the risk for ventricular tachyarrhythmias (e.g., torsades de pointes) or sudden death. IBTROZI prolongs the QTc interval in a concentration-dependent manner.In patients who received IBTROZI and underwent at least one post baseline ECG, QTcF increase of >60 msec compared to baseline and QTcF >500 msec occurred in 13% and 2.6% of patients, respectively. 3.4% of patients experienced Grade ≥3. Median time from first dose of IBTROZI to onset of ECG QT prolongation was 22 days (range: 1 day to 38.7 months). Dose interruption and dose reduction each occurred in 2.8% of patients.Significant QTc interval prolongation may occur when IBTROZI is taken with food, strong and moderate CYP3A inhibitors, and/or drugs with a known potential to prolong QTc. Administer IBTROZI on an empty stomach. Avoid concomitant use with strong and moderate CYP3A inhibitors and/or drugs with a known potential to prolong QTc.Hyperuricemia: Hyperuricemia can occur and was reported in 14% of patients, with 16% of these requiring urate-lowering medication without pre-existing gout or hyperuricemia. 0.3% of patients experienced Grade ≥3. Median time to first onset was 2.1 months (range: 7 days to 35.8 months). Dose interruption occurred in 0.3% of patients.Myalgia with Creatine Phosphokinase (CPK) Elevation: Myalgia with or without CPK elevation can occur. Myalgia occurred in 10% of patients. Median time to first onset was 11 days (range: 2 days to 10 months).Concurrent myalgia with increased CPK within a 7-day time period occurred in 0.9% of patients. Dose interruption occurred in 0.3% of patients with myalgia and concurrent CPK elevation.Skeletal Fractures: IBTROZI can increase the risk of fractures. ROS1 inhibitors as a class have been associated with skeletal fractures. 3.4% of patients experienced fractures, including 1.4% Grade 3. Some fractures occurred in the setting of a fall or other predisposing factors. Median time to first onset of fracture was 10.7 months (range: 26 days to 29.1 months). Dose interruption occurred in 0.3% of patients.Embryo-Fetal Toxicity: Based on literature, animal studies, and its mechanism of action, IBTROZI can cause fetal harm when administered to a pregnant woman.ADVERSE REACTIONSAmong patients who received IBTROZI, the most frequently reported adverse reactions (≥20%) were diarrhea (64%), nausea (47%), vomiting (43%), dizziness (22%), rash (22%), constipation (21%), and fatigue (20%).The most frequently reported Grade 3/4 laboratory abnormalities (≥5%) were increased ALT (13%), increased AST (10%), decreased neutrophils (5%), and increased creatine phosphokinase (5%).DRUG INTERACTIONSStrong and Moderate CYP3A Inhibitors/CYP3A Inducers and Drugs that Prolong the QTc Interval: Avoid concomitant use.Gastric Acid Reducing Agents: Avoid concomitant use with PPIs and H2 receptor antagonists. If an acid-reducing agent cannot be avoided, administer locally acting antacids at least 2 hours before or 2 hours after taking IBTROZI. OTHER CONSIDERATIONSPregnancy: Please see important information in Warnings and Precautions under Embryo-Fetal Toxicity.Lactation: Advise women not to breastfeed during treatment and for 3 weeks after the last dose.Effect on Fertility: Based on findings in animals, IBTROZI may impair fertility in males and females. The effects on animal fertility were reversible.Pediatric Use: The safety and effectiveness of IBTROZI in pediatric patients has not been established.Photosensitivity: IBTROZI can cause photosensitivity. Advise patients to minimize sun exposure and to use sun protection, including broad-spectrum sunscreen, during treatment and for at least 5 days after discontinuation. Please see accompanying full U.S. Prescribing Information.(1) Nuvation Bio Inc. IBTROZI (taletrectinib) US prescribing information. Available at: https://ibtrozipi.com/IBTROZI_taletrectinib-prescribing-information.pdf. Last accessed: March 2026(2) Wood R, Taylor-Stokes G. Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage. Available here. Last accessed: March 2026(3) European Lung Foundation. Lung cancer. Available here. Last accessed: March 2026(4) Patil T, Smith DE, Bunn PA Jr, et al. The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib. J Thorac Oncol. 2018;13(11):1717-1726. doi:10.1016/j.jtho.2018.07.012.(5) Drilon A, Camidge DR, Lin JJ, et al. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. N Engl J Med. 2024;390(2):118-131. doi:10.1056/NEJMoa2302299. (6) ClinicalTrials.gov. A Study of AB-106 in Advanced NSCLC With ROS1 Fusion (NCT04395677). Available at: https://clinicaltrials.gov/study/NCT04395677 . Last accessed: March 2026(7) ClinicalTrials.gov. A single-arm Phase 2 study of taletrectinib in advanced ROS1-positive NSCLC (NCT04919811). Available at: https://clinicaltrials.gov/study/NCT04919811 . Last accessed: March 2026(8) Pérol M, A., et al. Taletrectinib in ROS1-positive non-small cell lung cancer: TRUST. Journal of Clinical Oncology, 43(16), 1920–1929. https://doi.org/10.1200/JCO-25-00275(9) Global Data. Diagnosed incident cases of non-small cell lung cancer across 8MM to reach 1.46 million in 2032, forecasts GlobalData. Available here. Last accessed: March 2026(10) Patil T, Smith DE, Bunn PA Jr, et al. The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib. J Thorac Oncol. 2018;13(11):1717-1726. doi:10.1016/j.jtho.2018.07.012.(11) Drilon A, Camidge DR, Lin JJ, et al. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. N Engl J Med. 2024;390(2):118-131.MEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Nuvation Bio Inc.Kaitlyn Nealymedia@nuvationbio.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Nuvation Bio Inc.JR DeVitair@nuvationbio.comForward-Looking Statements of Nuvation Bio Inc.Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding taletrectinib’s therapeutic potential and the urgent need for new therapeutic options for patients with advanced ROS1+ NSCLC in Europe, our expectations that the MAA filing for taletrectinib will follow a standard review with a decision in 1H 2027 and be considered for full approval, plans for additional filings for the U.K., Canada and other regions included in Eisai’s licensed territories, and expectations for near-term disclosure of updated data. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from those anticipated by the forward-looking statements, including but not limited to the challenges associated with conducting drug discovery and commercialization, and initiating or conducting clinical studies due to, among other things, difficulties or delays in the regulatory process, enrolling subjects or manufacturing or acquiring necessary products; the emergence or worsening of adverse events or other undesirable side effects; risks associated with preliminary and interim data, which may not be representative of more mature data; physician and patient behavior; and competitive developments. Risks and uncertainties facing Nuvation Bio are described more fully in its Form 10-K filed with the SEC on March 2, 2026 under the heading “Risk Factors,” and other documents that Nuvation Bio has filed or will file with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

AffPapa Introduces Four New Exclusive Categories for AffPapa iGaming Awards 2026

admin

(AsiaGameHub) -   AffPapa is rolling out four exclusive new categories for the AffPapa iGaming Awards 2026, redirecting part of the spotlight from companies to the individuals driving the industry’s progress. While the awards have historically focused on honoring brands in the iGaming sector, this year’s edition expands that scope to also highlight personal accomplishments and leadership contributions. The newly added categories for the AffPapa iGaming Awards 2026 are as follows: Woman Leader of the Year CEO of the Year Affiliate Manager of the Year Best Employer of the Year Designed to be more selective and targeted, these categories place a greater emphasis on individual contributors and workplace culture, rather than overall company performance. Levon Nikoghosyan, CEO at AffPapa, stated: Behind every high-performing company, there are always teams carrying out core work and keeping operations running smoothly. We wanted to shine more light on that side of the industry this year, as these are the people who also shape its future trajectory. The decision to launch these new categories aligns with the event’s newly adopted theme, “The Test of Time”, which centers on consistency, resilience, and long-term impact, recognizing those who have remained relevant while supporting the industry’s growth. Registration for the AffPapa iGaming Awards 2026 is still open, with affiliates, operators, and B2B providers invited to submit their brands for nomination, including for the new categories. Winners will be announced at the awards ceremony on the final day of the AffPapa Conference Madrid, held from May 18–20. Companies and industry professionals can sign up for the AffPapa iGaming Awards 2026 through the official event website. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

Cambodia advances with a strict telecom fraud law featuring life imprisonment

admin

(AsiaGameHub) -   Cambodia is nearing the enactment of a specialized telecom fraud law—the first of its kind in the region—which could impose life imprisonment as a penalty. According to Koet Rith, Deputy Prime Minister and Minister of Justice, the Anti-Telecom Fraud Law has been approved by the cabinet and is now under review by the National Assembly’s legislative and judicial committee. Government officials state the law was drafted in response to the growing number of scams and fraudulent activities in the telecommunications sector and aims to prevent criminals from regrouping following recent crackdowns. Under the draft legislation, operators or managers of scam centers may face lengthy prison terms. Those who establish or run such facilities could be sentenced to 5 to 10 years in prison. However, if the operation involves unlawful detention, extortion, or homicide, the sentence could range from 30 years to life imprisonment. The bill will set penalties for those who recruit or train individuals for fraudulent operations and hold landlords and property owners responsible for leasing premises to such operations. The legislation will define offenses for five categories of individuals. This initiative follows multiple public remarks by Prime Minister Hun Manet, who emphasized that the government is undertaking a genuine and ongoing effort to address telecom fraud, not merely a superficial one. The Prime Minister has noted that this issue is not only a domestic problem but has also damaged Cambodia’s international reputation, meaning the reform carries political weight. The pace at which the bill is processed by relevant committee(s) to reach the National Assembly will shape the immediate next steps. The severity of life sentences and heavy fines for those involved in serious fraud cases underscores the government’s heightened efforts to shut down Cambodia’s top fraud hub and target its backers. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

Over 3000 Annual Gambling Licenses in South Africa Raise Concerns Among Lawmakers

admin

(AsiaGameHub) -   South Africa’s gambling sector has been drawing significant attention recently due to the high volume of annual license issuances, according to new parliamentary statistics. A parliamentary response from Rise Mzansi MP Makashule Gana confirmed that 3,135 licenses were issued for the 2024/2025 financial year—marginally down from 3,174 in the prior year and slightly below 3,186 in 2022/2023. The approval of such a large number of licenses has raised questions about whether the government can adequately monitor the gambling industry’s growth. Most licenses were granted to limited payout machines and bookmakers, which account for the majority of the sector’s growth. Police have stated that oversight in the gambling sector is insufficient. Questions have been raised about whether provincial boards have the appropriate resources to consistently enforce regulations related to consumer protection, responsible gambling, and financial reporting. There is growing concern that oversight from provincial boards is inconsistent across provinces, with some boards having significant resources and others having very few. Police reported a total of 32,938 illegal gambling cases over the last five financial years, with approximately 100% originating from land-based gambling establishments. During the same period, 36 online gambling cases were reported, resulting in 39 arrests and 22 convictions. Due to these issues, many legislators are calling for increased coordination between national and provincial authorities. Several proposals have been made to improve This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

EveryMatrix enhances its aggregation platform through partnership with Eeze

admin

(AsiaGameHub) -   EveryMatrix has successfully enhanced its aggregation platform through a partnership with Eeze, enabling its global partners to access Eeze’s live dealer and RNG content portfolio. The two most significant new additions to EveryMatrix’s platform are the recently introduced Fusion Roulette and Eeze’s inaugural slot games. Bjorn Sjoberg, Chief Commercial Officer at EveryMatrix, said: We are delighted to incorporate Eeze’s complete product suite into our aggregation offering. With top-tier live products and an exciting lineup of RNG games in development, we are confident our clients will appreciate the distinctiveness these titles bring to the market. Mikko Hoglund, Partnership Manager at Eeze, added: Collaborating with EveryMatrix is a pivotal moment for us as we aim to introduce our games to a broader player network than ever. We have several exciting product launches planned for the coming months and are confident these games, along with our existing portfolio, will be well-received by EveryMatrix’s client base. Similarly, EveryMatrix has been expanding its footprint in the US market. Last month, it partnered with Ocean Casino Resort in New Jersey, making a vast selection of over 45,000 titles from more than 360 suppliers accessible to players on Ocean Resort’s online platform, betOcean, via EveryMatrix’s casino platform. This marked EveryMatrix’s fifth partnership in North America and third in the United States. The company currently holds licenses in Connecticut, Michigan, New Jersey, Pennsylvania, and West Virginia, as well as in Ontario, Canada. Its associates include bet365, BetPark Delaware North, and Pinnacle. Mark Burroughes, Chief Commercial Officer of Casino at EveryMatrix, said at the time: Collaborating with betOcean is a critical step in our growth strategy. Achieving a full aggregation integration in under four months, including regulatory approval, demonstrates our extensive expertise in delivering compliant content in the US. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

17,000 individuals have joined a class action lawsuit against Norsk Tipping over lottery errors

admin

(AsiaGameHub) -   More than 17,000 individuals have signed onto a class action suit targeting Norsk Tipping, marking the biggest class action case ever recorded in Norway. Legal firm SANDS launched the action following confirmation that glitches in the Lotto and Eurojackpot draw systems had impacted participants' winning probabilities. The cutoff date for joining the legal action was February 16, 2026. Norway's gambling regulator reports that these malfunctions impacted numerous drawings carried out across several years. Lars Tormodsgard, a partner at SANDS, maintains that the issues caused players to face poorer chances than what was promoted, representing a critical defect in how these games functioned. Plaintiffs are demanding reimbursement for all wagers placed before the issue was discovered. Bets made during the affected timeframe stretching from 2015/2016 through 2025 span from minimal to substantial amounts. While the overall case value remains undetermined, the sheer number of participants suggests it could reach significant proportions. While Norsk Tipping has conceded that technical problems occurred, it rejects any legal responsibility. The company argues that the glitches only impacted supplementary draws and does not justify returning all stakes for every drawing. The operator has announced its intention to contest the claims in court. The lottery operator is also facing separate legal proceedings, alongside various regulatory penalties imposed in recent years that have accumulated to NOK 119 million (about $14 million) for assorted technical and operational breakdowns. This includes a NOK 46 million penalty specifically for drawing mistakes. Officials indicate this particular bug may have persisted for up to a decade, potentially giving organized betting groups a major advantage over solo players. Court proceedings are set to commence on August 25-26, 2016. The verdict will carry substantial financial consequences for Norsk Tipping and could establish a significant benchmark for addressing gambling industry mistakes within regulated markets. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

Playtech Sees 10% Revenue Drop in Fiscal 2025

admin

(AsiaGameHub) -   Playtech’s FY2025 results indicate that managing the restructuring and the sale of Snaitech proved challenging, leading to decreases in both revenue and earnings. Compared to FY2024, Total Group Revenue for FY2025 fell by $763.6 million (10%). Adjusted EBITDA decreased by $197 million (9%), which was slightly above initial forecasts thanks to better-than-anticipated operational performance in the US. Playtech also saw a decline in profitable operations, with post-tax profit from continuing operations dropping 28% to $44.2 million. The company reported a net loss attributable to operations of €169.5 million for the full year. However, total profit for the year reached €120.7 million when discontinued operations were included. The notable year-over-year difference in total profit stemmed from the absence of one-off gains that had been recorded in the previous fiscal year. Revenue from Playtech’s core B2B division fell by 9% to €688.3 million, and EBITDA fell by 36% to €141.4 million. These decreases were mainly driven by modifications to the Caliente agreement, which shifted earnings from revenue to investment income. If these changes are excluded, B2B revenue from regulated markets actually increased by 6%, accounting for more than 80% of total B2B revenue. After finalizing the €2.3 billion sale of Snaitech, Playtech’s financial standing has strengthened considerably, moving from a net debt position to a net cash position of €28.5 million. Alongside bolstering its finances, the company returned approximately €1.8 billion to shareholders via special dividends and share buybacks. The Snaitech deal has also realigned Playtech’s strategy to focus more on B2B and lower its overall exposure. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

Dow CEO ព្រមានថាកង្វះផលិតផលបេត្រូគីមីពីសង្គ្រាមអ៊ីរ៉ង់អាចជំរុញឧបត្ថម្ភសម្រាប់ផ្នែកដែលនៅសេសសល់នៃឆ្នាំនេះ

admin

(SeaPRwire) -   ការកើនឡើងថ្លៃនិងកង្វះខាតផលិតផលគីមីប្រេងដែលបណ្តាលមកពីសង្គ្រាមអ៊ីរ៉ង់ ទំនងជានឹងបង្កឱ្យមានផលប៉ះពាល់អាំងហ្វ្លេស្សិនយ៉ាងហោចណាស់រហូតដល់ចុងឆ្នាំលើសម្ភារៈសំណង់ ទំនិញប្រើប្រាស់ផ្ទាល់ ឧស្សាហកម្មយានយន្ត និងយានអវកាស និងច្រើនទៀត នេះបើតាមប្រធានប្រតិបត្តិ Dow chemical ។ ខណៈដែលការរងផលប៉ះពាល់ផ្គត់ផ្គង់ទូទាំងពិភពលោកភាគច្រើនផ្តោតលើប្រេង ឧស្ម័នធម្មជាតិ ជី និងសូម្បីតែហេលីយ៉ូមសម្រាប់អង្គធាតុពាក់កណ្តាលចម្រោះ ប្រហែល ២០% នៃសមត្ថភាពផលិតគីមីប្រេងពិភពលោកត្រូវបានរារាំងដោយសារការបិទច្រកហុមស៍ដែលជាចំណុចចង្អុលបង្ហាញដោយប្រសិទ្ធភាពរបស់អ៊ីរ៉ង់ នេះបើតាមប្រធាន និងប្រធានប្រតិបត្តិ Dow Jim Fitterling ។ "អ្វីដែលនឹងកើតឡើងនៅក្នុងទីផ្សារកំពុងត្រូវបានកំណត់សម្រាប់ឆ្នាំនេះទៀតហើយ" Fitterling បាននិយាយនៅក្នុងសន្និសីទ CERAWeek ដោយ S&P Global នៅទីក្រុង Houston ។ "វាដូចគ្នានឹងការរលាយខ្សែសង្វាក់ផ្គត់ផ្គង់ដែលយើងបានឃើញក្នុងអំឡុងពេល COVID ។ "អ្នកអាចនៅក្នុងចន្លោះ ២៥០ ទៅ ២៧៥ ថ្ងៃ។ វានឹងមិនមែនជាការត្រឡប់ក្រោយភ្លាមៗនោះទេ។" ការរងផលប៉ះពាល់ផ្គត់ផ្គង់នេះនឹងមិនត្រឹមតែធ្វើឱ្យវិន័យសេដ្ឋកិច្ចដែលគេហៅថា K-shaped កាន់តែធ្ងន់ធ្ងរឡើងប៉ុណ្ណោះទេ តែថែមទាំងបង្កើតភាពមិនស្មើគ្នាកាន់តែខ្លាំងរវាងអ្នកដែលមាន និងអ្នកដែលគ្មាន រវាងអឌ្ឍគោលខាងលិច និងខាងកើតទៀតផង ដូចដែលគាត់បាននិយាយ។ រោងចក្រផលិតគីមីប្រេងសំណល់នៅភាគខាងលិច — ដែលដឹកនាំដោយសហរដ្ឋអាមេរិក — ភាគច្រើនពឹងផ្អែកលើអេតានដែលមកពីឧស្ម័នធម្មជាតិជាវត្ថុធាតុដើមសំខាន់ ដែលមិនត្រូវបានជះឥទ្ធិពលដោយផ្ទាល់ដោយសង្គ្រាមនោះទេ។ នៅអាស៊ី និងភាគច្រើននៃអឺរ៉ុប ពួកគេប្រើណាផ្ថាដែលមានមូលដ្ឋានលើប្រេងក្រៅជាវត្ថុធាតុសំណង់។ ហើយជិតពាក់កណ្តាលនៃការផ្គត់ផ្គង់ណាផ្ថារបស់អាស៊ីហូរឆ្លងកាត់ច្រកហុមស៍ ដូចដែល Fitterling បានកត់សម្គាល់។ រួចមកហើយ រោងចក្រជាច្រើននៅអាស៊ីកំពុងប្រកាស force majeure និងកាត់បន្ថយផលិតកម្មយ៉ាងខ្លាំង ដោយសារតែពួកគេមិនអាចទទួលបានណាផ្ថានោះទេ នេះបើតាមអគ្គនាយករងផ្នែកស្រាវជ្រាវប្រេង ឥន្ធនៈ និងគីមីវិទ្យា S&P Global Energy Kurt Barrow ។ "យើងកំពុងឃើញការប្រកាស force majeure នៃរោងចក្រនៅអាស៊ី ប៉ុន្តែយើងមិនទាន់ឃើញការខ្វះខាតនៅ Home Depot នៅឡើយទេ" Barrow បាននិយាយទៅកាន់ ។ "ប៉ុន្តែមានសក្តានុពលនោះ។ គីមីវិទ្យាចូលទៅក្នុងអ្វីៗទាំងអស់។" របៀបដែលខ្សែសង្វាក់ផ្គត់ផ្គង់រីករាលដាល ខណៈដែលជាធម្មតា នាវា ១៥០ គ្រឿងហូរឆ្លងកាត់ច្រកហុមស៍ក្នុងមួយថ្ងៃ Fitterling ប៉ាន់ស្មានថា នាវាដែលមានអ្នកអមដំណើរត្រឹមតែប្រហែល ១៥ គ្រឿងប៉ុណ្ណោះ ដែលនឹងធ្វើដំណើរជាលើកដំបូងក្នុងមួយថ្ងៃ នៅពេលដែលច្រកសមុទ្រត្រូវបានបើកឡើងវិញនៅទីបំផុត។ ដំណើរការនេះនឹងចាប់ផ្តើមដោយផ្តល់អាទិភាពដល់ប្រេង និងឧស្ម័ន — ជាង ៣០០ នាវាក្នុងចំណោមនាវា ៤៣០ គ្រឿងដែលជាប់គាំង គឺជានាវាដឹកប្រេង — ហើយបន្ទាប់មកទំនងជាផ្តល់អាទិភាពទីពីរដល់ជីសម្រាប់កសិកម្ម និងការផ្គត់ផ្គង់អាហារ។ "ផលិតផលគីមីប្រេងនឹងស្ថិតនៅកន្លែងណាមួយនៅក្នុងបញ្ជី" Fitterling បាននិយាយ ហើយនាវាទាំងនោះត្រូវការពេលធ្វើដំណើរ ៤ សប្តាហ៍ទៅកាន់អាស៊ី។ "អ្នកត្រូវតែសម្អាតខ្សែសង្វាក់ផ្គត់ផ្គង់ចេញពីឈូងសមុទ្រអារ៉ាប់។" នោះហើយជាមូលហេតុដែលការកំណត់តម្លៃផលិតផលគីមីប្រេងសំណល់ជាមូលដ្ឋានរវាងសហរដ្ឋអាមេរិក និងអាស៊ី — ជាធម្មតាតិចជាង ៥០០ ដុល្លារក្នុងមួយតោន — បានកើនឡើងខ្ពស់ជាង ១,២០០ ដុល្លារ ដូចដែលគាត់បាននិយាយ។ តម្លៃនឹងនៅតែកើនឡើងនៅគ្រប់ទីកន្លែង។ "យើងត្រូវតែធ្វើដំណើរក្នុងសេដ្ឋកិច្ចដែលមានល្បឿនពីរ; យើងត្រូវតែធ្វើដំណើរក្នុងការរំខានភូមិសាស្ត្រនយោបាយដ៏ធំធេង" Fitterling បាននិយាយ។ "ភាពមិនស្ថិតស្ថេរកំពុងខ្ពស់ជាងក្រាហ្វិកឥឡូវនេះ។" នៅលើផ្ទៃ នេះជាដំណឹងល្អសម្រាប់ក្រុមហ៊ុនផលិតគីមីប្រេងរបស់សហរដ្ឋអាមេរិក។ ការរីកចម្រើនភាគច្រើនរបស់ Dow ក្នុងឆ្នាំថ្មីៗនេះគឺនៅ Texas, Louisiana, និង Canada ។ ប៉ុន្តែ Dow ដូចជាអ្នកលេងគីមីប្រេងកំពូលជាច្រើនទៀត គឺមានភាពចម្រុះ ហើយ Dow មានប្រតិបត្តិការសំខាន់ៗនៅអាស៊ី រួមទាំងគម្រោងរួមគ្នាធំៗនៅ Saudi Arabia ។ វិស័យគីមីប្រេងបានរងការធ្លាក់ចុះទូទាំងឧស្សាហកម្មក្នុងឆ្នាំថ្មីៗនេះ ហើយនៅចុងខែមករា Dow (លេខ ១០៣ នៅលើ ៥០០) បានប្រកាសផែនការ "transform to outperform" ដែលមានគោលបំណងសន្សំសំចៃ ២ ពាន់លានដុល្លារ រួមទាំងក អត្ថបទនេះត្រូវបានផ្តល់ជូនដោយអ្នកផ្គត់ផ្គង់មាតិកាដែលទីបញ្ចូល។ SeaPRwire (https://www.seaprwire.com/) មិនមានការធានា ឬ បញ្ចេញកំណត់ណាមួយ។ ប្រភេទ: ព័ត៌មានប្រចាំថ្ងៃ, ព័ត៌មានសំខាន់ SeaPRwire ផ្តល់សេវាកម្មផ្សាយពាណិជ្ជកម្មសារព័ត៌មានសកលសម្រាប់ក្រុមហ៊ុន និងស្ថាប័ន ដែលមានការចូលដំណើរការនៅលើបណ្ដាញមេឌៀជាង 6,500 បណ្ដាញ ប័ណ្ណប្រតិភូ 86,000 និងអ្នកសារព័ត៌មានជាង 350 លាន។ SeaPRwire គាំទ្រការផ្សាយពាណិជ្ជកម្មជាសារព័ត៌មានជាភាសាអង់គ្លេស ជប៉ុន ហ្រ្វាំង គូរី ហ្វ្រេនច រ៉ុស អ៊ីនដូនេស៊ី ម៉ាឡេស៊ី វៀតណាម ចិន និងភាសាផ្សេងទៀត។